la production des plaquettes sanguines - les …...la production des plaquettes sanguines jeudis de...

Post on 07-Jun-2020

3 Views

Category:

Documents

0 Downloads

Preview:

Click to see full reader

TRANSCRIPT

La production

des

plaquettes sanguines

Jeudis de Fleurus 2016

Prof Christian CHATELAIN

NTHC

Universiteacute de Namur

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

Plaquette sanguine

Plaquette sanguine

Plaquette sanguine

platelet

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

1910 Megakaryocyte (Wright)

1910 Megakaryocyte (Wright)

1910 Megakaryocyte (Wright)

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

Meacutethode isotopique

LA PRODUCTION DES PLAQUETTES

EST CONTROLEE

A humoral factor controls platelet production

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

1968 Le Nombre la Taille et la Ploiumldie des

meacutegacaryocytes sont sous controcircle (Harker)

Seacuterum anti-plaquettaire

Thrombocytopeacutenie

1968 Le Nombre la Taille et la Ploiumldie des

meacutegacaryocytes sont sous controcircle (Harker)

Transfusion de plaquettes

Thrombocytheacutemie

000

100

200

300

400

500

600

700

800

900

000 100 200 300 400 500 600 700 800 900 1000

Vo

lum

e M

eacutegac

aryo

cyta

ire

Mo

yen

(x1

00

0 micro

sup3)

Plaquettes (x100000microL)

Morphomeacutetrie

Normal

LMC

Tose 2aire

TOTAL

Lineacuteaire (TOTAL)

Hamood M amp Chatelain C 1984

000

200

400

600

800

1000

1200

1400

000 500 1000 1500 2000 2500

Vo

lum

e M

eacutegac

aryo

cyta

ire

Mo

yen

(x1

00

0 micro

sup3)

Plaquettes (x100000microL)

Morphomeacutetrie

Normal

LMC

Tose 2aire

TOTAL

PVET

Lineacuteaire (TOTAL)

PVET

Hamood M amp Chatelain C 1984

HYPERPLAQUETTOSE

REACTIONNELLE vs PRIMITIVE

Effort stress adreacutenaline

Infection inflamation

Carence en fer

Cancer

Vincristine

Aspleacutenie

SMP

LMCTE

Vaquez

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

1975 CFU-MK (Metcalf)

Hieacuterarchie cellulaire

PSC CFU-MKMeacutegacaryocytes Plaquettes

PSC CFU-MKMeacutegacaryocytes Plaquettes

IL-3 GM-CSF

LITHIUM ACETYLCHOLINE

CYCLOSPORINE A

lt 1050

LD-CFU-MK

lt 1050

LD-CFU-MK

PSC

CFU-MK Meacutegacaryocytes Plaquettes

LD-CFU-MK

TPO

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMegakaryocytes Platelets

IL-3 GM-CSF

IL-6 IL-11 LIF

Oncostatin M hellip

1983 Cytokines (Metcalf Quesenberryhellip)

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMeacutegacaryocytes Plaquettes

THROMBOPOIETINE

1994 THROMBOPOIETINE (mpl ligand)

THROMBOPOIETINE

1 mpl oncogene

2 Production constante

3 Stimulates proliferation

4 Controcircle POLYPLOIDISATION

5 LD-CFU-MK

6 Reacutegulation lsquo par produit final rsquo

cad par les plaquettes

THROMBOPOIETINE

APPLICATION

CLINIQUE DE LA

THROMBOPOIETINE

1 rh-TPO deacuteception

2 Dosage ITP hellip

3 Analogues TPO Nplatereg (Romiplostim)

et Revoladereg (Eltrombopag) PTI

4 Production in vitro de plaquettes

Platelet production in vitro

CD34 + cells

Platelets

7-14 days

D 14

D 14

GP-IIbIIIa

D 14

GP-IIIa

CD34Forward vs side

Scatter (d14)

Cells

0

2000000

4000000

6000000

J0 J3 J7 J10 J14

Platelets

0

200000000

400000000

600000000

800000000

1000000000

J0 J3 J7 J10 J14

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

IL-1α induces thrombopoiesis through megakaryocyte rupture in response to

acute platelet needs

Nishimura S1 Nagasaki M2 Kunishima S3 Sawaguchi A4 Sakata A5 Sakaguchi H6

Ohmori T5 Manabe I7 Italiano JE Jr8 Ryu T9 Takayama N10 Komuro I2

Kadowaki T2 Eto K11 Nagai R5

J Cell Biol 2015 May 11209(3)453-66

RUPTURE MEGACARYOCYTAIRE

En guise de conclusion

DIAGNOSTIC Drsquo

HYPERPLAQUETTOSE

La production

des

plaquettes sanguines

Jeudis de Fleurus 2016

Prof Christian CHATELAIN

NTHC

Universiteacute de Namur

POLYPLOIDISATION

MECHANISM

Role of cytoskeletton

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

HYDROXYUREA DECREASES

PROLIFERATION

ANAGRELIDE DECREASES

POLYPLOIDIZATION

PSC CFU-MKMegakaryocytes Platelets

HUDROXYUREA

ANAGRELIDE

THERAPY OF ET

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

Do not forget HYPERURICEMIA

(Allopurinol)

What about PLATELET FUNCTIONS

Pathogeny and treatment of

THROMBOCYTHEMIA

UNDERSTANDING

MEGAKARYOCYTOPOIESIS

2004

Prof Christian CHATELAIN

UCL MONT-GODINNE

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

Plaquette sanguine

Plaquette sanguine

Plaquette sanguine

platelet

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

1910 Megakaryocyte (Wright)

1910 Megakaryocyte (Wright)

1910 Megakaryocyte (Wright)

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

Meacutethode isotopique

LA PRODUCTION DES PLAQUETTES

EST CONTROLEE

A humoral factor controls platelet production

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

1968 Le Nombre la Taille et la Ploiumldie des

meacutegacaryocytes sont sous controcircle (Harker)

Seacuterum anti-plaquettaire

Thrombocytopeacutenie

1968 Le Nombre la Taille et la Ploiumldie des

meacutegacaryocytes sont sous controcircle (Harker)

Transfusion de plaquettes

Thrombocytheacutemie

000

100

200

300

400

500

600

700

800

900

000 100 200 300 400 500 600 700 800 900 1000

Vo

lum

e M

eacutegac

aryo

cyta

ire

Mo

yen

(x1

00

0 micro

sup3)

Plaquettes (x100000microL)

Morphomeacutetrie

Normal

LMC

Tose 2aire

TOTAL

Lineacuteaire (TOTAL)

Hamood M amp Chatelain C 1984

000

200

400

600

800

1000

1200

1400

000 500 1000 1500 2000 2500

Vo

lum

e M

eacutegac

aryo

cyta

ire

Mo

yen

(x1

00

0 micro

sup3)

Plaquettes (x100000microL)

Morphomeacutetrie

Normal

LMC

Tose 2aire

TOTAL

PVET

Lineacuteaire (TOTAL)

PVET

Hamood M amp Chatelain C 1984

HYPERPLAQUETTOSE

REACTIONNELLE vs PRIMITIVE

Effort stress adreacutenaline

Infection inflamation

Carence en fer

Cancer

Vincristine

Aspleacutenie

SMP

LMCTE

Vaquez

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

1975 CFU-MK (Metcalf)

Hieacuterarchie cellulaire

PSC CFU-MKMeacutegacaryocytes Plaquettes

PSC CFU-MKMeacutegacaryocytes Plaquettes

IL-3 GM-CSF

LITHIUM ACETYLCHOLINE

CYCLOSPORINE A

lt 1050

LD-CFU-MK

lt 1050

LD-CFU-MK

PSC

CFU-MK Meacutegacaryocytes Plaquettes

LD-CFU-MK

TPO

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMegakaryocytes Platelets

IL-3 GM-CSF

IL-6 IL-11 LIF

Oncostatin M hellip

1983 Cytokines (Metcalf Quesenberryhellip)

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMeacutegacaryocytes Plaquettes

THROMBOPOIETINE

1994 THROMBOPOIETINE (mpl ligand)

THROMBOPOIETINE

1 mpl oncogene

2 Production constante

3 Stimulates proliferation

4 Controcircle POLYPLOIDISATION

5 LD-CFU-MK

6 Reacutegulation lsquo par produit final rsquo

cad par les plaquettes

THROMBOPOIETINE

APPLICATION

CLINIQUE DE LA

THROMBOPOIETINE

1 rh-TPO deacuteception

2 Dosage ITP hellip

3 Analogues TPO Nplatereg (Romiplostim)

et Revoladereg (Eltrombopag) PTI

4 Production in vitro de plaquettes

Platelet production in vitro

CD34 + cells

Platelets

7-14 days

D 14

D 14

GP-IIbIIIa

D 14

GP-IIIa

CD34Forward vs side

Scatter (d14)

Cells

0

2000000

4000000

6000000

J0 J3 J7 J10 J14

Platelets

0

200000000

400000000

600000000

800000000

1000000000

J0 J3 J7 J10 J14

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

IL-1α induces thrombopoiesis through megakaryocyte rupture in response to

acute platelet needs

Nishimura S1 Nagasaki M2 Kunishima S3 Sawaguchi A4 Sakata A5 Sakaguchi H6

Ohmori T5 Manabe I7 Italiano JE Jr8 Ryu T9 Takayama N10 Komuro I2

Kadowaki T2 Eto K11 Nagai R5

J Cell Biol 2015 May 11209(3)453-66

RUPTURE MEGACARYOCYTAIRE

En guise de conclusion

DIAGNOSTIC Drsquo

HYPERPLAQUETTOSE

La production

des

plaquettes sanguines

Jeudis de Fleurus 2016

Prof Christian CHATELAIN

NTHC

Universiteacute de Namur

POLYPLOIDISATION

MECHANISM

Role of cytoskeletton

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

HYDROXYUREA DECREASES

PROLIFERATION

ANAGRELIDE DECREASES

POLYPLOIDIZATION

PSC CFU-MKMegakaryocytes Platelets

HUDROXYUREA

ANAGRELIDE

THERAPY OF ET

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

Do not forget HYPERURICEMIA

(Allopurinol)

What about PLATELET FUNCTIONS

Pathogeny and treatment of

THROMBOCYTHEMIA

UNDERSTANDING

MEGAKARYOCYTOPOIESIS

2004

Prof Christian CHATELAIN

UCL MONT-GODINNE

Plaquette sanguine

Plaquette sanguine

Plaquette sanguine

platelet

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

1910 Megakaryocyte (Wright)

1910 Megakaryocyte (Wright)

1910 Megakaryocyte (Wright)

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

Meacutethode isotopique

LA PRODUCTION DES PLAQUETTES

EST CONTROLEE

A humoral factor controls platelet production

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

1968 Le Nombre la Taille et la Ploiumldie des

meacutegacaryocytes sont sous controcircle (Harker)

Seacuterum anti-plaquettaire

Thrombocytopeacutenie

1968 Le Nombre la Taille et la Ploiumldie des

meacutegacaryocytes sont sous controcircle (Harker)

Transfusion de plaquettes

Thrombocytheacutemie

000

100

200

300

400

500

600

700

800

900

000 100 200 300 400 500 600 700 800 900 1000

Vo

lum

e M

eacutegac

aryo

cyta

ire

Mo

yen

(x1

00

0 micro

sup3)

Plaquettes (x100000microL)

Morphomeacutetrie

Normal

LMC

Tose 2aire

TOTAL

Lineacuteaire (TOTAL)

Hamood M amp Chatelain C 1984

000

200

400

600

800

1000

1200

1400

000 500 1000 1500 2000 2500

Vo

lum

e M

eacutegac

aryo

cyta

ire

Mo

yen

(x1

00

0 micro

sup3)

Plaquettes (x100000microL)

Morphomeacutetrie

Normal

LMC

Tose 2aire

TOTAL

PVET

Lineacuteaire (TOTAL)

PVET

Hamood M amp Chatelain C 1984

HYPERPLAQUETTOSE

REACTIONNELLE vs PRIMITIVE

Effort stress adreacutenaline

Infection inflamation

Carence en fer

Cancer

Vincristine

Aspleacutenie

SMP

LMCTE

Vaquez

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

1975 CFU-MK (Metcalf)

Hieacuterarchie cellulaire

PSC CFU-MKMeacutegacaryocytes Plaquettes

PSC CFU-MKMeacutegacaryocytes Plaquettes

IL-3 GM-CSF

LITHIUM ACETYLCHOLINE

CYCLOSPORINE A

lt 1050

LD-CFU-MK

lt 1050

LD-CFU-MK

PSC

CFU-MK Meacutegacaryocytes Plaquettes

LD-CFU-MK

TPO

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMegakaryocytes Platelets

IL-3 GM-CSF

IL-6 IL-11 LIF

Oncostatin M hellip

1983 Cytokines (Metcalf Quesenberryhellip)

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMeacutegacaryocytes Plaquettes

THROMBOPOIETINE

1994 THROMBOPOIETINE (mpl ligand)

THROMBOPOIETINE

1 mpl oncogene

2 Production constante

3 Stimulates proliferation

4 Controcircle POLYPLOIDISATION

5 LD-CFU-MK

6 Reacutegulation lsquo par produit final rsquo

cad par les plaquettes

THROMBOPOIETINE

APPLICATION

CLINIQUE DE LA

THROMBOPOIETINE

1 rh-TPO deacuteception

2 Dosage ITP hellip

3 Analogues TPO Nplatereg (Romiplostim)

et Revoladereg (Eltrombopag) PTI

4 Production in vitro de plaquettes

Platelet production in vitro

CD34 + cells

Platelets

7-14 days

D 14

D 14

GP-IIbIIIa

D 14

GP-IIIa

CD34Forward vs side

Scatter (d14)

Cells

0

2000000

4000000

6000000

J0 J3 J7 J10 J14

Platelets

0

200000000

400000000

600000000

800000000

1000000000

J0 J3 J7 J10 J14

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

IL-1α induces thrombopoiesis through megakaryocyte rupture in response to

acute platelet needs

Nishimura S1 Nagasaki M2 Kunishima S3 Sawaguchi A4 Sakata A5 Sakaguchi H6

Ohmori T5 Manabe I7 Italiano JE Jr8 Ryu T9 Takayama N10 Komuro I2

Kadowaki T2 Eto K11 Nagai R5

J Cell Biol 2015 May 11209(3)453-66

RUPTURE MEGACARYOCYTAIRE

En guise de conclusion

DIAGNOSTIC Drsquo

HYPERPLAQUETTOSE

La production

des

plaquettes sanguines

Jeudis de Fleurus 2016

Prof Christian CHATELAIN

NTHC

Universiteacute de Namur

POLYPLOIDISATION

MECHANISM

Role of cytoskeletton

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

HYDROXYUREA DECREASES

PROLIFERATION

ANAGRELIDE DECREASES

POLYPLOIDIZATION

PSC CFU-MKMegakaryocytes Platelets

HUDROXYUREA

ANAGRELIDE

THERAPY OF ET

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

Do not forget HYPERURICEMIA

(Allopurinol)

What about PLATELET FUNCTIONS

Pathogeny and treatment of

THROMBOCYTHEMIA

UNDERSTANDING

MEGAKARYOCYTOPOIESIS

2004

Prof Christian CHATELAIN

UCL MONT-GODINNE

Plaquette sanguine

Plaquette sanguine

platelet

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

1910 Megakaryocyte (Wright)

1910 Megakaryocyte (Wright)

1910 Megakaryocyte (Wright)

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

Meacutethode isotopique

LA PRODUCTION DES PLAQUETTES

EST CONTROLEE

A humoral factor controls platelet production

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

1968 Le Nombre la Taille et la Ploiumldie des

meacutegacaryocytes sont sous controcircle (Harker)

Seacuterum anti-plaquettaire

Thrombocytopeacutenie

1968 Le Nombre la Taille et la Ploiumldie des

meacutegacaryocytes sont sous controcircle (Harker)

Transfusion de plaquettes

Thrombocytheacutemie

000

100

200

300

400

500

600

700

800

900

000 100 200 300 400 500 600 700 800 900 1000

Vo

lum

e M

eacutegac

aryo

cyta

ire

Mo

yen

(x1

00

0 micro

sup3)

Plaquettes (x100000microL)

Morphomeacutetrie

Normal

LMC

Tose 2aire

TOTAL

Lineacuteaire (TOTAL)

Hamood M amp Chatelain C 1984

000

200

400

600

800

1000

1200

1400

000 500 1000 1500 2000 2500

Vo

lum

e M

eacutegac

aryo

cyta

ire

Mo

yen

(x1

00

0 micro

sup3)

Plaquettes (x100000microL)

Morphomeacutetrie

Normal

LMC

Tose 2aire

TOTAL

PVET

Lineacuteaire (TOTAL)

PVET

Hamood M amp Chatelain C 1984

HYPERPLAQUETTOSE

REACTIONNELLE vs PRIMITIVE

Effort stress adreacutenaline

Infection inflamation

Carence en fer

Cancer

Vincristine

Aspleacutenie

SMP

LMCTE

Vaquez

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

1975 CFU-MK (Metcalf)

Hieacuterarchie cellulaire

PSC CFU-MKMeacutegacaryocytes Plaquettes

PSC CFU-MKMeacutegacaryocytes Plaquettes

IL-3 GM-CSF

LITHIUM ACETYLCHOLINE

CYCLOSPORINE A

lt 1050

LD-CFU-MK

lt 1050

LD-CFU-MK

PSC

CFU-MK Meacutegacaryocytes Plaquettes

LD-CFU-MK

TPO

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMegakaryocytes Platelets

IL-3 GM-CSF

IL-6 IL-11 LIF

Oncostatin M hellip

1983 Cytokines (Metcalf Quesenberryhellip)

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMeacutegacaryocytes Plaquettes

THROMBOPOIETINE

1994 THROMBOPOIETINE (mpl ligand)

THROMBOPOIETINE

1 mpl oncogene

2 Production constante

3 Stimulates proliferation

4 Controcircle POLYPLOIDISATION

5 LD-CFU-MK

6 Reacutegulation lsquo par produit final rsquo

cad par les plaquettes

THROMBOPOIETINE

APPLICATION

CLINIQUE DE LA

THROMBOPOIETINE

1 rh-TPO deacuteception

2 Dosage ITP hellip

3 Analogues TPO Nplatereg (Romiplostim)

et Revoladereg (Eltrombopag) PTI

4 Production in vitro de plaquettes

Platelet production in vitro

CD34 + cells

Platelets

7-14 days

D 14

D 14

GP-IIbIIIa

D 14

GP-IIIa

CD34Forward vs side

Scatter (d14)

Cells

0

2000000

4000000

6000000

J0 J3 J7 J10 J14

Platelets

0

200000000

400000000

600000000

800000000

1000000000

J0 J3 J7 J10 J14

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

IL-1α induces thrombopoiesis through megakaryocyte rupture in response to

acute platelet needs

Nishimura S1 Nagasaki M2 Kunishima S3 Sawaguchi A4 Sakata A5 Sakaguchi H6

Ohmori T5 Manabe I7 Italiano JE Jr8 Ryu T9 Takayama N10 Komuro I2

Kadowaki T2 Eto K11 Nagai R5

J Cell Biol 2015 May 11209(3)453-66

RUPTURE MEGACARYOCYTAIRE

En guise de conclusion

DIAGNOSTIC Drsquo

HYPERPLAQUETTOSE

La production

des

plaquettes sanguines

Jeudis de Fleurus 2016

Prof Christian CHATELAIN

NTHC

Universiteacute de Namur

POLYPLOIDISATION

MECHANISM

Role of cytoskeletton

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

HYDROXYUREA DECREASES

PROLIFERATION

ANAGRELIDE DECREASES

POLYPLOIDIZATION

PSC CFU-MKMegakaryocytes Platelets

HUDROXYUREA

ANAGRELIDE

THERAPY OF ET

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

Do not forget HYPERURICEMIA

(Allopurinol)

What about PLATELET FUNCTIONS

Pathogeny and treatment of

THROMBOCYTHEMIA

UNDERSTANDING

MEGAKARYOCYTOPOIESIS

2004

Prof Christian CHATELAIN

UCL MONT-GODINNE

Plaquette sanguine

platelet

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

1910 Megakaryocyte (Wright)

1910 Megakaryocyte (Wright)

1910 Megakaryocyte (Wright)

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

Meacutethode isotopique

LA PRODUCTION DES PLAQUETTES

EST CONTROLEE

A humoral factor controls platelet production

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

1968 Le Nombre la Taille et la Ploiumldie des

meacutegacaryocytes sont sous controcircle (Harker)

Seacuterum anti-plaquettaire

Thrombocytopeacutenie

1968 Le Nombre la Taille et la Ploiumldie des

meacutegacaryocytes sont sous controcircle (Harker)

Transfusion de plaquettes

Thrombocytheacutemie

000

100

200

300

400

500

600

700

800

900

000 100 200 300 400 500 600 700 800 900 1000

Vo

lum

e M

eacutegac

aryo

cyta

ire

Mo

yen

(x1

00

0 micro

sup3)

Plaquettes (x100000microL)

Morphomeacutetrie

Normal

LMC

Tose 2aire

TOTAL

Lineacuteaire (TOTAL)

Hamood M amp Chatelain C 1984

000

200

400

600

800

1000

1200

1400

000 500 1000 1500 2000 2500

Vo

lum

e M

eacutegac

aryo

cyta

ire

Mo

yen

(x1

00

0 micro

sup3)

Plaquettes (x100000microL)

Morphomeacutetrie

Normal

LMC

Tose 2aire

TOTAL

PVET

Lineacuteaire (TOTAL)

PVET

Hamood M amp Chatelain C 1984

HYPERPLAQUETTOSE

REACTIONNELLE vs PRIMITIVE

Effort stress adreacutenaline

Infection inflamation

Carence en fer

Cancer

Vincristine

Aspleacutenie

SMP

LMCTE

Vaquez

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

1975 CFU-MK (Metcalf)

Hieacuterarchie cellulaire

PSC CFU-MKMeacutegacaryocytes Plaquettes

PSC CFU-MKMeacutegacaryocytes Plaquettes

IL-3 GM-CSF

LITHIUM ACETYLCHOLINE

CYCLOSPORINE A

lt 1050

LD-CFU-MK

lt 1050

LD-CFU-MK

PSC

CFU-MK Meacutegacaryocytes Plaquettes

LD-CFU-MK

TPO

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMegakaryocytes Platelets

IL-3 GM-CSF

IL-6 IL-11 LIF

Oncostatin M hellip

1983 Cytokines (Metcalf Quesenberryhellip)

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMeacutegacaryocytes Plaquettes

THROMBOPOIETINE

1994 THROMBOPOIETINE (mpl ligand)

THROMBOPOIETINE

1 mpl oncogene

2 Production constante

3 Stimulates proliferation

4 Controcircle POLYPLOIDISATION

5 LD-CFU-MK

6 Reacutegulation lsquo par produit final rsquo

cad par les plaquettes

THROMBOPOIETINE

APPLICATION

CLINIQUE DE LA

THROMBOPOIETINE

1 rh-TPO deacuteception

2 Dosage ITP hellip

3 Analogues TPO Nplatereg (Romiplostim)

et Revoladereg (Eltrombopag) PTI

4 Production in vitro de plaquettes

Platelet production in vitro

CD34 + cells

Platelets

7-14 days

D 14

D 14

GP-IIbIIIa

D 14

GP-IIIa

CD34Forward vs side

Scatter (d14)

Cells

0

2000000

4000000

6000000

J0 J3 J7 J10 J14

Platelets

0

200000000

400000000

600000000

800000000

1000000000

J0 J3 J7 J10 J14

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

IL-1α induces thrombopoiesis through megakaryocyte rupture in response to

acute platelet needs

Nishimura S1 Nagasaki M2 Kunishima S3 Sawaguchi A4 Sakata A5 Sakaguchi H6

Ohmori T5 Manabe I7 Italiano JE Jr8 Ryu T9 Takayama N10 Komuro I2

Kadowaki T2 Eto K11 Nagai R5

J Cell Biol 2015 May 11209(3)453-66

RUPTURE MEGACARYOCYTAIRE

En guise de conclusion

DIAGNOSTIC Drsquo

HYPERPLAQUETTOSE

La production

des

plaquettes sanguines

Jeudis de Fleurus 2016

Prof Christian CHATELAIN

NTHC

Universiteacute de Namur

POLYPLOIDISATION

MECHANISM

Role of cytoskeletton

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

HYDROXYUREA DECREASES

PROLIFERATION

ANAGRELIDE DECREASES

POLYPLOIDIZATION

PSC CFU-MKMegakaryocytes Platelets

HUDROXYUREA

ANAGRELIDE

THERAPY OF ET

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

Do not forget HYPERURICEMIA

(Allopurinol)

What about PLATELET FUNCTIONS

Pathogeny and treatment of

THROMBOCYTHEMIA

UNDERSTANDING

MEGAKARYOCYTOPOIESIS

2004

Prof Christian CHATELAIN

UCL MONT-GODINNE

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

1910 Megakaryocyte (Wright)

1910 Megakaryocyte (Wright)

1910 Megakaryocyte (Wright)

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

Meacutethode isotopique

LA PRODUCTION DES PLAQUETTES

EST CONTROLEE

A humoral factor controls platelet production

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

1968 Le Nombre la Taille et la Ploiumldie des

meacutegacaryocytes sont sous controcircle (Harker)

Seacuterum anti-plaquettaire

Thrombocytopeacutenie

1968 Le Nombre la Taille et la Ploiumldie des

meacutegacaryocytes sont sous controcircle (Harker)

Transfusion de plaquettes

Thrombocytheacutemie

000

100

200

300

400

500

600

700

800

900

000 100 200 300 400 500 600 700 800 900 1000

Vo

lum

e M

eacutegac

aryo

cyta

ire

Mo

yen

(x1

00

0 micro

sup3)

Plaquettes (x100000microL)

Morphomeacutetrie

Normal

LMC

Tose 2aire

TOTAL

Lineacuteaire (TOTAL)

Hamood M amp Chatelain C 1984

000

200

400

600

800

1000

1200

1400

000 500 1000 1500 2000 2500

Vo

lum

e M

eacutegac

aryo

cyta

ire

Mo

yen

(x1

00

0 micro

sup3)

Plaquettes (x100000microL)

Morphomeacutetrie

Normal

LMC

Tose 2aire

TOTAL

PVET

Lineacuteaire (TOTAL)

PVET

Hamood M amp Chatelain C 1984

HYPERPLAQUETTOSE

REACTIONNELLE vs PRIMITIVE

Effort stress adreacutenaline

Infection inflamation

Carence en fer

Cancer

Vincristine

Aspleacutenie

SMP

LMCTE

Vaquez

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

1975 CFU-MK (Metcalf)

Hieacuterarchie cellulaire

PSC CFU-MKMeacutegacaryocytes Plaquettes

PSC CFU-MKMeacutegacaryocytes Plaquettes

IL-3 GM-CSF

LITHIUM ACETYLCHOLINE

CYCLOSPORINE A

lt 1050

LD-CFU-MK

lt 1050

LD-CFU-MK

PSC

CFU-MK Meacutegacaryocytes Plaquettes

LD-CFU-MK

TPO

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMegakaryocytes Platelets

IL-3 GM-CSF

IL-6 IL-11 LIF

Oncostatin M hellip

1983 Cytokines (Metcalf Quesenberryhellip)

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMeacutegacaryocytes Plaquettes

THROMBOPOIETINE

1994 THROMBOPOIETINE (mpl ligand)

THROMBOPOIETINE

1 mpl oncogene

2 Production constante

3 Stimulates proliferation

4 Controcircle POLYPLOIDISATION

5 LD-CFU-MK

6 Reacutegulation lsquo par produit final rsquo

cad par les plaquettes

THROMBOPOIETINE

APPLICATION

CLINIQUE DE LA

THROMBOPOIETINE

1 rh-TPO deacuteception

2 Dosage ITP hellip

3 Analogues TPO Nplatereg (Romiplostim)

et Revoladereg (Eltrombopag) PTI

4 Production in vitro de plaquettes

Platelet production in vitro

CD34 + cells

Platelets

7-14 days

D 14

D 14

GP-IIbIIIa

D 14

GP-IIIa

CD34Forward vs side

Scatter (d14)

Cells

0

2000000

4000000

6000000

J0 J3 J7 J10 J14

Platelets

0

200000000

400000000

600000000

800000000

1000000000

J0 J3 J7 J10 J14

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

IL-1α induces thrombopoiesis through megakaryocyte rupture in response to

acute platelet needs

Nishimura S1 Nagasaki M2 Kunishima S3 Sawaguchi A4 Sakata A5 Sakaguchi H6

Ohmori T5 Manabe I7 Italiano JE Jr8 Ryu T9 Takayama N10 Komuro I2

Kadowaki T2 Eto K11 Nagai R5

J Cell Biol 2015 May 11209(3)453-66

RUPTURE MEGACARYOCYTAIRE

En guise de conclusion

DIAGNOSTIC Drsquo

HYPERPLAQUETTOSE

La production

des

plaquettes sanguines

Jeudis de Fleurus 2016

Prof Christian CHATELAIN

NTHC

Universiteacute de Namur

POLYPLOIDISATION

MECHANISM

Role of cytoskeletton

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

HYDROXYUREA DECREASES

PROLIFERATION

ANAGRELIDE DECREASES

POLYPLOIDIZATION

PSC CFU-MKMegakaryocytes Platelets

HUDROXYUREA

ANAGRELIDE

THERAPY OF ET

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

Do not forget HYPERURICEMIA

(Allopurinol)

What about PLATELET FUNCTIONS

Pathogeny and treatment of

THROMBOCYTHEMIA

UNDERSTANDING

MEGAKARYOCYTOPOIESIS

2004

Prof Christian CHATELAIN

UCL MONT-GODINNE

1910 Megakaryocyte (Wright)

1910 Megakaryocyte (Wright)

1910 Megakaryocyte (Wright)

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

Meacutethode isotopique

LA PRODUCTION DES PLAQUETTES

EST CONTROLEE

A humoral factor controls platelet production

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

1968 Le Nombre la Taille et la Ploiumldie des

meacutegacaryocytes sont sous controcircle (Harker)

Seacuterum anti-plaquettaire

Thrombocytopeacutenie

1968 Le Nombre la Taille et la Ploiumldie des

meacutegacaryocytes sont sous controcircle (Harker)

Transfusion de plaquettes

Thrombocytheacutemie

000

100

200

300

400

500

600

700

800

900

000 100 200 300 400 500 600 700 800 900 1000

Vo

lum

e M

eacutegac

aryo

cyta

ire

Mo

yen

(x1

00

0 micro

sup3)

Plaquettes (x100000microL)

Morphomeacutetrie

Normal

LMC

Tose 2aire

TOTAL

Lineacuteaire (TOTAL)

Hamood M amp Chatelain C 1984

000

200

400

600

800

1000

1200

1400

000 500 1000 1500 2000 2500

Vo

lum

e M

eacutegac

aryo

cyta

ire

Mo

yen

(x1

00

0 micro

sup3)

Plaquettes (x100000microL)

Morphomeacutetrie

Normal

LMC

Tose 2aire

TOTAL

PVET

Lineacuteaire (TOTAL)

PVET

Hamood M amp Chatelain C 1984

HYPERPLAQUETTOSE

REACTIONNELLE vs PRIMITIVE

Effort stress adreacutenaline

Infection inflamation

Carence en fer

Cancer

Vincristine

Aspleacutenie

SMP

LMCTE

Vaquez

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

1975 CFU-MK (Metcalf)

Hieacuterarchie cellulaire

PSC CFU-MKMeacutegacaryocytes Plaquettes

PSC CFU-MKMeacutegacaryocytes Plaquettes

IL-3 GM-CSF

LITHIUM ACETYLCHOLINE

CYCLOSPORINE A

lt 1050

LD-CFU-MK

lt 1050

LD-CFU-MK

PSC

CFU-MK Meacutegacaryocytes Plaquettes

LD-CFU-MK

TPO

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMegakaryocytes Platelets

IL-3 GM-CSF

IL-6 IL-11 LIF

Oncostatin M hellip

1983 Cytokines (Metcalf Quesenberryhellip)

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMeacutegacaryocytes Plaquettes

THROMBOPOIETINE

1994 THROMBOPOIETINE (mpl ligand)

THROMBOPOIETINE

1 mpl oncogene

2 Production constante

3 Stimulates proliferation

4 Controcircle POLYPLOIDISATION

5 LD-CFU-MK

6 Reacutegulation lsquo par produit final rsquo

cad par les plaquettes

THROMBOPOIETINE

APPLICATION

CLINIQUE DE LA

THROMBOPOIETINE

1 rh-TPO deacuteception

2 Dosage ITP hellip

3 Analogues TPO Nplatereg (Romiplostim)

et Revoladereg (Eltrombopag) PTI

4 Production in vitro de plaquettes

Platelet production in vitro

CD34 + cells

Platelets

7-14 days

D 14

D 14

GP-IIbIIIa

D 14

GP-IIIa

CD34Forward vs side

Scatter (d14)

Cells

0

2000000

4000000

6000000

J0 J3 J7 J10 J14

Platelets

0

200000000

400000000

600000000

800000000

1000000000

J0 J3 J7 J10 J14

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

IL-1α induces thrombopoiesis through megakaryocyte rupture in response to

acute platelet needs

Nishimura S1 Nagasaki M2 Kunishima S3 Sawaguchi A4 Sakata A5 Sakaguchi H6

Ohmori T5 Manabe I7 Italiano JE Jr8 Ryu T9 Takayama N10 Komuro I2

Kadowaki T2 Eto K11 Nagai R5

J Cell Biol 2015 May 11209(3)453-66

RUPTURE MEGACARYOCYTAIRE

En guise de conclusion

DIAGNOSTIC Drsquo

HYPERPLAQUETTOSE

La production

des

plaquettes sanguines

Jeudis de Fleurus 2016

Prof Christian CHATELAIN

NTHC

Universiteacute de Namur

POLYPLOIDISATION

MECHANISM

Role of cytoskeletton

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

HYDROXYUREA DECREASES

PROLIFERATION

ANAGRELIDE DECREASES

POLYPLOIDIZATION

PSC CFU-MKMegakaryocytes Platelets

HUDROXYUREA

ANAGRELIDE

THERAPY OF ET

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

Do not forget HYPERURICEMIA

(Allopurinol)

What about PLATELET FUNCTIONS

Pathogeny and treatment of

THROMBOCYTHEMIA

UNDERSTANDING

MEGAKARYOCYTOPOIESIS

2004

Prof Christian CHATELAIN

UCL MONT-GODINNE

1910 Megakaryocyte (Wright)

1910 Megakaryocyte (Wright)

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

Meacutethode isotopique

LA PRODUCTION DES PLAQUETTES

EST CONTROLEE

A humoral factor controls platelet production

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

1968 Le Nombre la Taille et la Ploiumldie des

meacutegacaryocytes sont sous controcircle (Harker)

Seacuterum anti-plaquettaire

Thrombocytopeacutenie

1968 Le Nombre la Taille et la Ploiumldie des

meacutegacaryocytes sont sous controcircle (Harker)

Transfusion de plaquettes

Thrombocytheacutemie

000

100

200

300

400

500

600

700

800

900

000 100 200 300 400 500 600 700 800 900 1000

Vo

lum

e M

eacutegac

aryo

cyta

ire

Mo

yen

(x1

00

0 micro

sup3)

Plaquettes (x100000microL)

Morphomeacutetrie

Normal

LMC

Tose 2aire

TOTAL

Lineacuteaire (TOTAL)

Hamood M amp Chatelain C 1984

000

200

400

600

800

1000

1200

1400

000 500 1000 1500 2000 2500

Vo

lum

e M

eacutegac

aryo

cyta

ire

Mo

yen

(x1

00

0 micro

sup3)

Plaquettes (x100000microL)

Morphomeacutetrie

Normal

LMC

Tose 2aire

TOTAL

PVET

Lineacuteaire (TOTAL)

PVET

Hamood M amp Chatelain C 1984

HYPERPLAQUETTOSE

REACTIONNELLE vs PRIMITIVE

Effort stress adreacutenaline

Infection inflamation

Carence en fer

Cancer

Vincristine

Aspleacutenie

SMP

LMCTE

Vaquez

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

1975 CFU-MK (Metcalf)

Hieacuterarchie cellulaire

PSC CFU-MKMeacutegacaryocytes Plaquettes

PSC CFU-MKMeacutegacaryocytes Plaquettes

IL-3 GM-CSF

LITHIUM ACETYLCHOLINE

CYCLOSPORINE A

lt 1050

LD-CFU-MK

lt 1050

LD-CFU-MK

PSC

CFU-MK Meacutegacaryocytes Plaquettes

LD-CFU-MK

TPO

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMegakaryocytes Platelets

IL-3 GM-CSF

IL-6 IL-11 LIF

Oncostatin M hellip

1983 Cytokines (Metcalf Quesenberryhellip)

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMeacutegacaryocytes Plaquettes

THROMBOPOIETINE

1994 THROMBOPOIETINE (mpl ligand)

THROMBOPOIETINE

1 mpl oncogene

2 Production constante

3 Stimulates proliferation

4 Controcircle POLYPLOIDISATION

5 LD-CFU-MK

6 Reacutegulation lsquo par produit final rsquo

cad par les plaquettes

THROMBOPOIETINE

APPLICATION

CLINIQUE DE LA

THROMBOPOIETINE

1 rh-TPO deacuteception

2 Dosage ITP hellip

3 Analogues TPO Nplatereg (Romiplostim)

et Revoladereg (Eltrombopag) PTI

4 Production in vitro de plaquettes

Platelet production in vitro

CD34 + cells

Platelets

7-14 days

D 14

D 14

GP-IIbIIIa

D 14

GP-IIIa

CD34Forward vs side

Scatter (d14)

Cells

0

2000000

4000000

6000000

J0 J3 J7 J10 J14

Platelets

0

200000000

400000000

600000000

800000000

1000000000

J0 J3 J7 J10 J14

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

IL-1α induces thrombopoiesis through megakaryocyte rupture in response to

acute platelet needs

Nishimura S1 Nagasaki M2 Kunishima S3 Sawaguchi A4 Sakata A5 Sakaguchi H6

Ohmori T5 Manabe I7 Italiano JE Jr8 Ryu T9 Takayama N10 Komuro I2

Kadowaki T2 Eto K11 Nagai R5

J Cell Biol 2015 May 11209(3)453-66

RUPTURE MEGACARYOCYTAIRE

En guise de conclusion

DIAGNOSTIC Drsquo

HYPERPLAQUETTOSE

La production

des

plaquettes sanguines

Jeudis de Fleurus 2016

Prof Christian CHATELAIN

NTHC

Universiteacute de Namur

POLYPLOIDISATION

MECHANISM

Role of cytoskeletton

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

HYDROXYUREA DECREASES

PROLIFERATION

ANAGRELIDE DECREASES

POLYPLOIDIZATION

PSC CFU-MKMegakaryocytes Platelets

HUDROXYUREA

ANAGRELIDE

THERAPY OF ET

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

Do not forget HYPERURICEMIA

(Allopurinol)

What about PLATELET FUNCTIONS

Pathogeny and treatment of

THROMBOCYTHEMIA

UNDERSTANDING

MEGAKARYOCYTOPOIESIS

2004

Prof Christian CHATELAIN

UCL MONT-GODINNE

1910 Megakaryocyte (Wright)

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

Meacutethode isotopique

LA PRODUCTION DES PLAQUETTES

EST CONTROLEE

A humoral factor controls platelet production

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

1968 Le Nombre la Taille et la Ploiumldie des

meacutegacaryocytes sont sous controcircle (Harker)

Seacuterum anti-plaquettaire

Thrombocytopeacutenie

1968 Le Nombre la Taille et la Ploiumldie des

meacutegacaryocytes sont sous controcircle (Harker)

Transfusion de plaquettes

Thrombocytheacutemie

000

100

200

300

400

500

600

700

800

900

000 100 200 300 400 500 600 700 800 900 1000

Vo

lum

e M

eacutegac

aryo

cyta

ire

Mo

yen

(x1

00

0 micro

sup3)

Plaquettes (x100000microL)

Morphomeacutetrie

Normal

LMC

Tose 2aire

TOTAL

Lineacuteaire (TOTAL)

Hamood M amp Chatelain C 1984

000

200

400

600

800

1000

1200

1400

000 500 1000 1500 2000 2500

Vo

lum

e M

eacutegac

aryo

cyta

ire

Mo

yen

(x1

00

0 micro

sup3)

Plaquettes (x100000microL)

Morphomeacutetrie

Normal

LMC

Tose 2aire

TOTAL

PVET

Lineacuteaire (TOTAL)

PVET

Hamood M amp Chatelain C 1984

HYPERPLAQUETTOSE

REACTIONNELLE vs PRIMITIVE

Effort stress adreacutenaline

Infection inflamation

Carence en fer

Cancer

Vincristine

Aspleacutenie

SMP

LMCTE

Vaquez

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

1975 CFU-MK (Metcalf)

Hieacuterarchie cellulaire

PSC CFU-MKMeacutegacaryocytes Plaquettes

PSC CFU-MKMeacutegacaryocytes Plaquettes

IL-3 GM-CSF

LITHIUM ACETYLCHOLINE

CYCLOSPORINE A

lt 1050

LD-CFU-MK

lt 1050

LD-CFU-MK

PSC

CFU-MK Meacutegacaryocytes Plaquettes

LD-CFU-MK

TPO

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMegakaryocytes Platelets

IL-3 GM-CSF

IL-6 IL-11 LIF

Oncostatin M hellip

1983 Cytokines (Metcalf Quesenberryhellip)

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMeacutegacaryocytes Plaquettes

THROMBOPOIETINE

1994 THROMBOPOIETINE (mpl ligand)

THROMBOPOIETINE

1 mpl oncogene

2 Production constante

3 Stimulates proliferation

4 Controcircle POLYPLOIDISATION

5 LD-CFU-MK

6 Reacutegulation lsquo par produit final rsquo

cad par les plaquettes

THROMBOPOIETINE

APPLICATION

CLINIQUE DE LA

THROMBOPOIETINE

1 rh-TPO deacuteception

2 Dosage ITP hellip

3 Analogues TPO Nplatereg (Romiplostim)

et Revoladereg (Eltrombopag) PTI

4 Production in vitro de plaquettes

Platelet production in vitro

CD34 + cells

Platelets

7-14 days

D 14

D 14

GP-IIbIIIa

D 14

GP-IIIa

CD34Forward vs side

Scatter (d14)

Cells

0

2000000

4000000

6000000

J0 J3 J7 J10 J14

Platelets

0

200000000

400000000

600000000

800000000

1000000000

J0 J3 J7 J10 J14

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

IL-1α induces thrombopoiesis through megakaryocyte rupture in response to

acute platelet needs

Nishimura S1 Nagasaki M2 Kunishima S3 Sawaguchi A4 Sakata A5 Sakaguchi H6

Ohmori T5 Manabe I7 Italiano JE Jr8 Ryu T9 Takayama N10 Komuro I2

Kadowaki T2 Eto K11 Nagai R5

J Cell Biol 2015 May 11209(3)453-66

RUPTURE MEGACARYOCYTAIRE

En guise de conclusion

DIAGNOSTIC Drsquo

HYPERPLAQUETTOSE

La production

des

plaquettes sanguines

Jeudis de Fleurus 2016

Prof Christian CHATELAIN

NTHC

Universiteacute de Namur

POLYPLOIDISATION

MECHANISM

Role of cytoskeletton

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

HYDROXYUREA DECREASES

PROLIFERATION

ANAGRELIDE DECREASES

POLYPLOIDIZATION

PSC CFU-MKMegakaryocytes Platelets

HUDROXYUREA

ANAGRELIDE

THERAPY OF ET

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

Do not forget HYPERURICEMIA

(Allopurinol)

What about PLATELET FUNCTIONS

Pathogeny and treatment of

THROMBOCYTHEMIA

UNDERSTANDING

MEGAKARYOCYTOPOIESIS

2004

Prof Christian CHATELAIN

UCL MONT-GODINNE

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

Meacutethode isotopique

LA PRODUCTION DES PLAQUETTES

EST CONTROLEE

A humoral factor controls platelet production

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

1968 Le Nombre la Taille et la Ploiumldie des

meacutegacaryocytes sont sous controcircle (Harker)

Seacuterum anti-plaquettaire

Thrombocytopeacutenie

1968 Le Nombre la Taille et la Ploiumldie des

meacutegacaryocytes sont sous controcircle (Harker)

Transfusion de plaquettes

Thrombocytheacutemie

000

100

200

300

400

500

600

700

800

900

000 100 200 300 400 500 600 700 800 900 1000

Vo

lum

e M

eacutegac

aryo

cyta

ire

Mo

yen

(x1

00

0 micro

sup3)

Plaquettes (x100000microL)

Morphomeacutetrie

Normal

LMC

Tose 2aire

TOTAL

Lineacuteaire (TOTAL)

Hamood M amp Chatelain C 1984

000

200

400

600

800

1000

1200

1400

000 500 1000 1500 2000 2500

Vo

lum

e M

eacutegac

aryo

cyta

ire

Mo

yen

(x1

00

0 micro

sup3)

Plaquettes (x100000microL)

Morphomeacutetrie

Normal

LMC

Tose 2aire

TOTAL

PVET

Lineacuteaire (TOTAL)

PVET

Hamood M amp Chatelain C 1984

HYPERPLAQUETTOSE

REACTIONNELLE vs PRIMITIVE

Effort stress adreacutenaline

Infection inflamation

Carence en fer

Cancer

Vincristine

Aspleacutenie

SMP

LMCTE

Vaquez

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

1975 CFU-MK (Metcalf)

Hieacuterarchie cellulaire

PSC CFU-MKMeacutegacaryocytes Plaquettes

PSC CFU-MKMeacutegacaryocytes Plaquettes

IL-3 GM-CSF

LITHIUM ACETYLCHOLINE

CYCLOSPORINE A

lt 1050

LD-CFU-MK

lt 1050

LD-CFU-MK

PSC

CFU-MK Meacutegacaryocytes Plaquettes

LD-CFU-MK

TPO

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMegakaryocytes Platelets

IL-3 GM-CSF

IL-6 IL-11 LIF

Oncostatin M hellip

1983 Cytokines (Metcalf Quesenberryhellip)

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMeacutegacaryocytes Plaquettes

THROMBOPOIETINE

1994 THROMBOPOIETINE (mpl ligand)

THROMBOPOIETINE

1 mpl oncogene

2 Production constante

3 Stimulates proliferation

4 Controcircle POLYPLOIDISATION

5 LD-CFU-MK

6 Reacutegulation lsquo par produit final rsquo

cad par les plaquettes

THROMBOPOIETINE

APPLICATION

CLINIQUE DE LA

THROMBOPOIETINE

1 rh-TPO deacuteception

2 Dosage ITP hellip

3 Analogues TPO Nplatereg (Romiplostim)

et Revoladereg (Eltrombopag) PTI

4 Production in vitro de plaquettes

Platelet production in vitro

CD34 + cells

Platelets

7-14 days

D 14

D 14

GP-IIbIIIa

D 14

GP-IIIa

CD34Forward vs side

Scatter (d14)

Cells

0

2000000

4000000

6000000

J0 J3 J7 J10 J14

Platelets

0

200000000

400000000

600000000

800000000

1000000000

J0 J3 J7 J10 J14

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

IL-1α induces thrombopoiesis through megakaryocyte rupture in response to

acute platelet needs

Nishimura S1 Nagasaki M2 Kunishima S3 Sawaguchi A4 Sakata A5 Sakaguchi H6

Ohmori T5 Manabe I7 Italiano JE Jr8 Ryu T9 Takayama N10 Komuro I2

Kadowaki T2 Eto K11 Nagai R5

J Cell Biol 2015 May 11209(3)453-66

RUPTURE MEGACARYOCYTAIRE

En guise de conclusion

DIAGNOSTIC Drsquo

HYPERPLAQUETTOSE

La production

des

plaquettes sanguines

Jeudis de Fleurus 2016

Prof Christian CHATELAIN

NTHC

Universiteacute de Namur

POLYPLOIDISATION

MECHANISM

Role of cytoskeletton

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

HYDROXYUREA DECREASES

PROLIFERATION

ANAGRELIDE DECREASES

POLYPLOIDIZATION

PSC CFU-MKMegakaryocytes Platelets

HUDROXYUREA

ANAGRELIDE

THERAPY OF ET

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

Do not forget HYPERURICEMIA

(Allopurinol)

What about PLATELET FUNCTIONS

Pathogeny and treatment of

THROMBOCYTHEMIA

UNDERSTANDING

MEGAKARYOCYTOPOIESIS

2004

Prof Christian CHATELAIN

UCL MONT-GODINNE

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

Meacutethode isotopique

LA PRODUCTION DES PLAQUETTES

EST CONTROLEE

A humoral factor controls platelet production

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

1968 Le Nombre la Taille et la Ploiumldie des

meacutegacaryocytes sont sous controcircle (Harker)

Seacuterum anti-plaquettaire

Thrombocytopeacutenie

1968 Le Nombre la Taille et la Ploiumldie des

meacutegacaryocytes sont sous controcircle (Harker)

Transfusion de plaquettes

Thrombocytheacutemie

000

100

200

300

400

500

600

700

800

900

000 100 200 300 400 500 600 700 800 900 1000

Vo

lum

e M

eacutegac

aryo

cyta

ire

Mo

yen

(x1

00

0 micro

sup3)

Plaquettes (x100000microL)

Morphomeacutetrie

Normal

LMC

Tose 2aire

TOTAL

Lineacuteaire (TOTAL)

Hamood M amp Chatelain C 1984

000

200

400

600

800

1000

1200

1400

000 500 1000 1500 2000 2500

Vo

lum

e M

eacutegac

aryo

cyta

ire

Mo

yen

(x1

00

0 micro

sup3)

Plaquettes (x100000microL)

Morphomeacutetrie

Normal

LMC

Tose 2aire

TOTAL

PVET

Lineacuteaire (TOTAL)

PVET

Hamood M amp Chatelain C 1984

HYPERPLAQUETTOSE

REACTIONNELLE vs PRIMITIVE

Effort stress adreacutenaline

Infection inflamation

Carence en fer

Cancer

Vincristine

Aspleacutenie

SMP

LMCTE

Vaquez

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

1975 CFU-MK (Metcalf)

Hieacuterarchie cellulaire

PSC CFU-MKMeacutegacaryocytes Plaquettes

PSC CFU-MKMeacutegacaryocytes Plaquettes

IL-3 GM-CSF

LITHIUM ACETYLCHOLINE

CYCLOSPORINE A

lt 1050

LD-CFU-MK

lt 1050

LD-CFU-MK

PSC

CFU-MK Meacutegacaryocytes Plaquettes

LD-CFU-MK

TPO

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMegakaryocytes Platelets

IL-3 GM-CSF

IL-6 IL-11 LIF

Oncostatin M hellip

1983 Cytokines (Metcalf Quesenberryhellip)

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMeacutegacaryocytes Plaquettes

THROMBOPOIETINE

1994 THROMBOPOIETINE (mpl ligand)

THROMBOPOIETINE

1 mpl oncogene

2 Production constante

3 Stimulates proliferation

4 Controcircle POLYPLOIDISATION

5 LD-CFU-MK

6 Reacutegulation lsquo par produit final rsquo

cad par les plaquettes

THROMBOPOIETINE

APPLICATION

CLINIQUE DE LA

THROMBOPOIETINE

1 rh-TPO deacuteception

2 Dosage ITP hellip

3 Analogues TPO Nplatereg (Romiplostim)

et Revoladereg (Eltrombopag) PTI

4 Production in vitro de plaquettes

Platelet production in vitro

CD34 + cells

Platelets

7-14 days

D 14

D 14

GP-IIbIIIa

D 14

GP-IIIa

CD34Forward vs side

Scatter (d14)

Cells

0

2000000

4000000

6000000

J0 J3 J7 J10 J14

Platelets

0

200000000

400000000

600000000

800000000

1000000000

J0 J3 J7 J10 J14

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

IL-1α induces thrombopoiesis through megakaryocyte rupture in response to

acute platelet needs

Nishimura S1 Nagasaki M2 Kunishima S3 Sawaguchi A4 Sakata A5 Sakaguchi H6

Ohmori T5 Manabe I7 Italiano JE Jr8 Ryu T9 Takayama N10 Komuro I2

Kadowaki T2 Eto K11 Nagai R5

J Cell Biol 2015 May 11209(3)453-66

RUPTURE MEGACARYOCYTAIRE

En guise de conclusion

DIAGNOSTIC Drsquo

HYPERPLAQUETTOSE

La production

des

plaquettes sanguines

Jeudis de Fleurus 2016

Prof Christian CHATELAIN

NTHC

Universiteacute de Namur

POLYPLOIDISATION

MECHANISM

Role of cytoskeletton

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

HYDROXYUREA DECREASES

PROLIFERATION

ANAGRELIDE DECREASES

POLYPLOIDIZATION

PSC CFU-MKMegakaryocytes Platelets

HUDROXYUREA

ANAGRELIDE

THERAPY OF ET

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

Do not forget HYPERURICEMIA

(Allopurinol)

What about PLATELET FUNCTIONS

Pathogeny and treatment of

THROMBOCYTHEMIA

UNDERSTANDING

MEGAKARYOCYTOPOIESIS

2004

Prof Christian CHATELAIN

UCL MONT-GODINNE

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

1968 Le Nombre la Taille et la Ploiumldie des

meacutegacaryocytes sont sous controcircle (Harker)

Seacuterum anti-plaquettaire

Thrombocytopeacutenie

1968 Le Nombre la Taille et la Ploiumldie des

meacutegacaryocytes sont sous controcircle (Harker)

Transfusion de plaquettes

Thrombocytheacutemie

000

100

200

300

400

500

600

700

800

900

000 100 200 300 400 500 600 700 800 900 1000

Vo

lum

e M

eacutegac

aryo

cyta

ire

Mo

yen

(x1

00

0 micro

sup3)

Plaquettes (x100000microL)

Morphomeacutetrie

Normal

LMC

Tose 2aire

TOTAL

Lineacuteaire (TOTAL)

Hamood M amp Chatelain C 1984

000

200

400

600

800

1000

1200

1400

000 500 1000 1500 2000 2500

Vo

lum

e M

eacutegac

aryo

cyta

ire

Mo

yen

(x1

00

0 micro

sup3)

Plaquettes (x100000microL)

Morphomeacutetrie

Normal

LMC

Tose 2aire

TOTAL

PVET

Lineacuteaire (TOTAL)

PVET

Hamood M amp Chatelain C 1984

HYPERPLAQUETTOSE

REACTIONNELLE vs PRIMITIVE

Effort stress adreacutenaline

Infection inflamation

Carence en fer

Cancer

Vincristine

Aspleacutenie

SMP

LMCTE

Vaquez

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

1975 CFU-MK (Metcalf)

Hieacuterarchie cellulaire

PSC CFU-MKMeacutegacaryocytes Plaquettes

PSC CFU-MKMeacutegacaryocytes Plaquettes

IL-3 GM-CSF

LITHIUM ACETYLCHOLINE

CYCLOSPORINE A

lt 1050

LD-CFU-MK

lt 1050

LD-CFU-MK

PSC

CFU-MK Meacutegacaryocytes Plaquettes

LD-CFU-MK

TPO

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMegakaryocytes Platelets

IL-3 GM-CSF

IL-6 IL-11 LIF

Oncostatin M hellip

1983 Cytokines (Metcalf Quesenberryhellip)

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMeacutegacaryocytes Plaquettes

THROMBOPOIETINE

1994 THROMBOPOIETINE (mpl ligand)

THROMBOPOIETINE

1 mpl oncogene

2 Production constante

3 Stimulates proliferation

4 Controcircle POLYPLOIDISATION

5 LD-CFU-MK

6 Reacutegulation lsquo par produit final rsquo

cad par les plaquettes

THROMBOPOIETINE

APPLICATION

CLINIQUE DE LA

THROMBOPOIETINE

1 rh-TPO deacuteception

2 Dosage ITP hellip

3 Analogues TPO Nplatereg (Romiplostim)

et Revoladereg (Eltrombopag) PTI

4 Production in vitro de plaquettes

Platelet production in vitro

CD34 + cells

Platelets

7-14 days

D 14

D 14

GP-IIbIIIa

D 14

GP-IIIa

CD34Forward vs side

Scatter (d14)

Cells

0

2000000

4000000

6000000

J0 J3 J7 J10 J14

Platelets

0

200000000

400000000

600000000

800000000

1000000000

J0 J3 J7 J10 J14

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

IL-1α induces thrombopoiesis through megakaryocyte rupture in response to

acute platelet needs

Nishimura S1 Nagasaki M2 Kunishima S3 Sawaguchi A4 Sakata A5 Sakaguchi H6

Ohmori T5 Manabe I7 Italiano JE Jr8 Ryu T9 Takayama N10 Komuro I2

Kadowaki T2 Eto K11 Nagai R5

J Cell Biol 2015 May 11209(3)453-66

RUPTURE MEGACARYOCYTAIRE

En guise de conclusion

DIAGNOSTIC Drsquo

HYPERPLAQUETTOSE

La production

des

plaquettes sanguines

Jeudis de Fleurus 2016

Prof Christian CHATELAIN

NTHC

Universiteacute de Namur

POLYPLOIDISATION

MECHANISM

Role of cytoskeletton

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

HYDROXYUREA DECREASES

PROLIFERATION

ANAGRELIDE DECREASES

POLYPLOIDIZATION

PSC CFU-MKMegakaryocytes Platelets

HUDROXYUREA

ANAGRELIDE

THERAPY OF ET

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

Do not forget HYPERURICEMIA

(Allopurinol)

What about PLATELET FUNCTIONS

Pathogeny and treatment of

THROMBOCYTHEMIA

UNDERSTANDING

MEGAKARYOCYTOPOIESIS

2004

Prof Christian CHATELAIN

UCL MONT-GODINNE

1968 Le Nombre la Taille et la Ploiumldie des

meacutegacaryocytes sont sous controcircle (Harker)

Seacuterum anti-plaquettaire

Thrombocytopeacutenie

1968 Le Nombre la Taille et la Ploiumldie des

meacutegacaryocytes sont sous controcircle (Harker)

Transfusion de plaquettes

Thrombocytheacutemie

000

100

200

300

400

500

600

700

800

900

000 100 200 300 400 500 600 700 800 900 1000

Vo

lum

e M

eacutegac

aryo

cyta

ire

Mo

yen

(x1

00

0 micro

sup3)

Plaquettes (x100000microL)

Morphomeacutetrie

Normal

LMC

Tose 2aire

TOTAL

Lineacuteaire (TOTAL)

Hamood M amp Chatelain C 1984

000

200

400

600

800

1000

1200

1400

000 500 1000 1500 2000 2500

Vo

lum

e M

eacutegac

aryo

cyta

ire

Mo

yen

(x1

00

0 micro

sup3)

Plaquettes (x100000microL)

Morphomeacutetrie

Normal

LMC

Tose 2aire

TOTAL

PVET

Lineacuteaire (TOTAL)

PVET

Hamood M amp Chatelain C 1984

HYPERPLAQUETTOSE

REACTIONNELLE vs PRIMITIVE

Effort stress adreacutenaline

Infection inflamation

Carence en fer

Cancer

Vincristine

Aspleacutenie

SMP

LMCTE

Vaquez

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

1975 CFU-MK (Metcalf)

Hieacuterarchie cellulaire

PSC CFU-MKMeacutegacaryocytes Plaquettes

PSC CFU-MKMeacutegacaryocytes Plaquettes

IL-3 GM-CSF

LITHIUM ACETYLCHOLINE

CYCLOSPORINE A

lt 1050

LD-CFU-MK

lt 1050

LD-CFU-MK

PSC

CFU-MK Meacutegacaryocytes Plaquettes

LD-CFU-MK

TPO

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMegakaryocytes Platelets

IL-3 GM-CSF

IL-6 IL-11 LIF

Oncostatin M hellip

1983 Cytokines (Metcalf Quesenberryhellip)

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMeacutegacaryocytes Plaquettes

THROMBOPOIETINE

1994 THROMBOPOIETINE (mpl ligand)

THROMBOPOIETINE

1 mpl oncogene

2 Production constante

3 Stimulates proliferation

4 Controcircle POLYPLOIDISATION

5 LD-CFU-MK

6 Reacutegulation lsquo par produit final rsquo

cad par les plaquettes

THROMBOPOIETINE

APPLICATION

CLINIQUE DE LA

THROMBOPOIETINE

1 rh-TPO deacuteception

2 Dosage ITP hellip

3 Analogues TPO Nplatereg (Romiplostim)

et Revoladereg (Eltrombopag) PTI

4 Production in vitro de plaquettes

Platelet production in vitro

CD34 + cells

Platelets

7-14 days

D 14

D 14

GP-IIbIIIa

D 14

GP-IIIa

CD34Forward vs side

Scatter (d14)

Cells

0

2000000

4000000

6000000

J0 J3 J7 J10 J14

Platelets

0

200000000

400000000

600000000

800000000

1000000000

J0 J3 J7 J10 J14

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

IL-1α induces thrombopoiesis through megakaryocyte rupture in response to

acute platelet needs

Nishimura S1 Nagasaki M2 Kunishima S3 Sawaguchi A4 Sakata A5 Sakaguchi H6

Ohmori T5 Manabe I7 Italiano JE Jr8 Ryu T9 Takayama N10 Komuro I2

Kadowaki T2 Eto K11 Nagai R5

J Cell Biol 2015 May 11209(3)453-66

RUPTURE MEGACARYOCYTAIRE

En guise de conclusion

DIAGNOSTIC Drsquo

HYPERPLAQUETTOSE

La production

des

plaquettes sanguines

Jeudis de Fleurus 2016

Prof Christian CHATELAIN

NTHC

Universiteacute de Namur

POLYPLOIDISATION

MECHANISM

Role of cytoskeletton

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

HYDROXYUREA DECREASES

PROLIFERATION

ANAGRELIDE DECREASES

POLYPLOIDIZATION

PSC CFU-MKMegakaryocytes Platelets

HUDROXYUREA

ANAGRELIDE

THERAPY OF ET

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

Do not forget HYPERURICEMIA

(Allopurinol)

What about PLATELET FUNCTIONS

Pathogeny and treatment of

THROMBOCYTHEMIA

UNDERSTANDING

MEGAKARYOCYTOPOIESIS

2004

Prof Christian CHATELAIN

UCL MONT-GODINNE

1968 Le Nombre la Taille et la Ploiumldie des

meacutegacaryocytes sont sous controcircle (Harker)

Transfusion de plaquettes

Thrombocytheacutemie

000

100

200

300

400

500

600

700

800

900

000 100 200 300 400 500 600 700 800 900 1000

Vo

lum

e M

eacutegac

aryo

cyta

ire

Mo

yen

(x1

00

0 micro

sup3)

Plaquettes (x100000microL)

Morphomeacutetrie

Normal

LMC

Tose 2aire

TOTAL

Lineacuteaire (TOTAL)

Hamood M amp Chatelain C 1984

000

200

400

600

800

1000

1200

1400

000 500 1000 1500 2000 2500

Vo

lum

e M

eacutegac

aryo

cyta

ire

Mo

yen

(x1

00

0 micro

sup3)

Plaquettes (x100000microL)

Morphomeacutetrie

Normal

LMC

Tose 2aire

TOTAL

PVET

Lineacuteaire (TOTAL)

PVET

Hamood M amp Chatelain C 1984

HYPERPLAQUETTOSE

REACTIONNELLE vs PRIMITIVE

Effort stress adreacutenaline

Infection inflamation

Carence en fer

Cancer

Vincristine

Aspleacutenie

SMP

LMCTE

Vaquez

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

1975 CFU-MK (Metcalf)

Hieacuterarchie cellulaire

PSC CFU-MKMeacutegacaryocytes Plaquettes

PSC CFU-MKMeacutegacaryocytes Plaquettes

IL-3 GM-CSF

LITHIUM ACETYLCHOLINE

CYCLOSPORINE A

lt 1050

LD-CFU-MK

lt 1050

LD-CFU-MK

PSC

CFU-MK Meacutegacaryocytes Plaquettes

LD-CFU-MK

TPO

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMegakaryocytes Platelets

IL-3 GM-CSF

IL-6 IL-11 LIF

Oncostatin M hellip

1983 Cytokines (Metcalf Quesenberryhellip)

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMeacutegacaryocytes Plaquettes

THROMBOPOIETINE

1994 THROMBOPOIETINE (mpl ligand)

THROMBOPOIETINE

1 mpl oncogene

2 Production constante

3 Stimulates proliferation

4 Controcircle POLYPLOIDISATION

5 LD-CFU-MK

6 Reacutegulation lsquo par produit final rsquo

cad par les plaquettes

THROMBOPOIETINE

APPLICATION

CLINIQUE DE LA

THROMBOPOIETINE

1 rh-TPO deacuteception

2 Dosage ITP hellip

3 Analogues TPO Nplatereg (Romiplostim)

et Revoladereg (Eltrombopag) PTI

4 Production in vitro de plaquettes

Platelet production in vitro

CD34 + cells

Platelets

7-14 days

D 14

D 14

GP-IIbIIIa

D 14

GP-IIIa

CD34Forward vs side

Scatter (d14)

Cells

0

2000000

4000000

6000000

J0 J3 J7 J10 J14

Platelets

0

200000000

400000000

600000000

800000000

1000000000

J0 J3 J7 J10 J14

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

IL-1α induces thrombopoiesis through megakaryocyte rupture in response to

acute platelet needs

Nishimura S1 Nagasaki M2 Kunishima S3 Sawaguchi A4 Sakata A5 Sakaguchi H6

Ohmori T5 Manabe I7 Italiano JE Jr8 Ryu T9 Takayama N10 Komuro I2

Kadowaki T2 Eto K11 Nagai R5

J Cell Biol 2015 May 11209(3)453-66

RUPTURE MEGACARYOCYTAIRE

En guise de conclusion

DIAGNOSTIC Drsquo

HYPERPLAQUETTOSE

La production

des

plaquettes sanguines

Jeudis de Fleurus 2016

Prof Christian CHATELAIN

NTHC

Universiteacute de Namur

POLYPLOIDISATION

MECHANISM

Role of cytoskeletton

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

HYDROXYUREA DECREASES

PROLIFERATION

ANAGRELIDE DECREASES

POLYPLOIDIZATION

PSC CFU-MKMegakaryocytes Platelets

HUDROXYUREA

ANAGRELIDE

THERAPY OF ET

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

Do not forget HYPERURICEMIA

(Allopurinol)

What about PLATELET FUNCTIONS

Pathogeny and treatment of

THROMBOCYTHEMIA

UNDERSTANDING

MEGAKARYOCYTOPOIESIS

2004

Prof Christian CHATELAIN

UCL MONT-GODINNE

000

100

200

300

400

500

600

700

800

900

000 100 200 300 400 500 600 700 800 900 1000

Vo

lum

e M

eacutegac

aryo

cyta

ire

Mo

yen

(x1

00

0 micro

sup3)

Plaquettes (x100000microL)

Morphomeacutetrie

Normal

LMC

Tose 2aire

TOTAL

Lineacuteaire (TOTAL)

Hamood M amp Chatelain C 1984

000

200

400

600

800

1000

1200

1400

000 500 1000 1500 2000 2500

Vo

lum

e M

eacutegac

aryo

cyta

ire

Mo

yen

(x1

00

0 micro

sup3)

Plaquettes (x100000microL)

Morphomeacutetrie

Normal

LMC

Tose 2aire

TOTAL

PVET

Lineacuteaire (TOTAL)

PVET

Hamood M amp Chatelain C 1984

HYPERPLAQUETTOSE

REACTIONNELLE vs PRIMITIVE

Effort stress adreacutenaline

Infection inflamation

Carence en fer

Cancer

Vincristine

Aspleacutenie

SMP

LMCTE

Vaquez

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

1975 CFU-MK (Metcalf)

Hieacuterarchie cellulaire

PSC CFU-MKMeacutegacaryocytes Plaquettes

PSC CFU-MKMeacutegacaryocytes Plaquettes

IL-3 GM-CSF

LITHIUM ACETYLCHOLINE

CYCLOSPORINE A

lt 1050

LD-CFU-MK

lt 1050

LD-CFU-MK

PSC

CFU-MK Meacutegacaryocytes Plaquettes

LD-CFU-MK

TPO

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMegakaryocytes Platelets

IL-3 GM-CSF

IL-6 IL-11 LIF

Oncostatin M hellip

1983 Cytokines (Metcalf Quesenberryhellip)

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMeacutegacaryocytes Plaquettes

THROMBOPOIETINE

1994 THROMBOPOIETINE (mpl ligand)

THROMBOPOIETINE

1 mpl oncogene

2 Production constante

3 Stimulates proliferation

4 Controcircle POLYPLOIDISATION

5 LD-CFU-MK

6 Reacutegulation lsquo par produit final rsquo

cad par les plaquettes

THROMBOPOIETINE

APPLICATION

CLINIQUE DE LA

THROMBOPOIETINE

1 rh-TPO deacuteception

2 Dosage ITP hellip

3 Analogues TPO Nplatereg (Romiplostim)

et Revoladereg (Eltrombopag) PTI

4 Production in vitro de plaquettes

Platelet production in vitro

CD34 + cells

Platelets

7-14 days

D 14

D 14

GP-IIbIIIa

D 14

GP-IIIa

CD34Forward vs side

Scatter (d14)

Cells

0

2000000

4000000

6000000

J0 J3 J7 J10 J14

Platelets

0

200000000

400000000

600000000

800000000

1000000000

J0 J3 J7 J10 J14

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

IL-1α induces thrombopoiesis through megakaryocyte rupture in response to

acute platelet needs

Nishimura S1 Nagasaki M2 Kunishima S3 Sawaguchi A4 Sakata A5 Sakaguchi H6

Ohmori T5 Manabe I7 Italiano JE Jr8 Ryu T9 Takayama N10 Komuro I2

Kadowaki T2 Eto K11 Nagai R5

J Cell Biol 2015 May 11209(3)453-66

RUPTURE MEGACARYOCYTAIRE

En guise de conclusion

DIAGNOSTIC Drsquo

HYPERPLAQUETTOSE

La production

des

plaquettes sanguines

Jeudis de Fleurus 2016

Prof Christian CHATELAIN

NTHC

Universiteacute de Namur

POLYPLOIDISATION

MECHANISM

Role of cytoskeletton

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

HYDROXYUREA DECREASES

PROLIFERATION

ANAGRELIDE DECREASES

POLYPLOIDIZATION

PSC CFU-MKMegakaryocytes Platelets

HUDROXYUREA

ANAGRELIDE

THERAPY OF ET

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

Do not forget HYPERURICEMIA

(Allopurinol)

What about PLATELET FUNCTIONS

Pathogeny and treatment of

THROMBOCYTHEMIA

UNDERSTANDING

MEGAKARYOCYTOPOIESIS

2004

Prof Christian CHATELAIN

UCL MONT-GODINNE

000

200

400

600

800

1000

1200

1400

000 500 1000 1500 2000 2500

Vo

lum

e M

eacutegac

aryo

cyta

ire

Mo

yen

(x1

00

0 micro

sup3)

Plaquettes (x100000microL)

Morphomeacutetrie

Normal

LMC

Tose 2aire

TOTAL

PVET

Lineacuteaire (TOTAL)

PVET

Hamood M amp Chatelain C 1984

HYPERPLAQUETTOSE

REACTIONNELLE vs PRIMITIVE

Effort stress adreacutenaline

Infection inflamation

Carence en fer

Cancer

Vincristine

Aspleacutenie

SMP

LMCTE

Vaquez

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

1975 CFU-MK (Metcalf)

Hieacuterarchie cellulaire

PSC CFU-MKMeacutegacaryocytes Plaquettes

PSC CFU-MKMeacutegacaryocytes Plaquettes

IL-3 GM-CSF

LITHIUM ACETYLCHOLINE

CYCLOSPORINE A

lt 1050

LD-CFU-MK

lt 1050

LD-CFU-MK

PSC

CFU-MK Meacutegacaryocytes Plaquettes

LD-CFU-MK

TPO

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMegakaryocytes Platelets

IL-3 GM-CSF

IL-6 IL-11 LIF

Oncostatin M hellip

1983 Cytokines (Metcalf Quesenberryhellip)

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMeacutegacaryocytes Plaquettes

THROMBOPOIETINE

1994 THROMBOPOIETINE (mpl ligand)

THROMBOPOIETINE

1 mpl oncogene

2 Production constante

3 Stimulates proliferation

4 Controcircle POLYPLOIDISATION

5 LD-CFU-MK

6 Reacutegulation lsquo par produit final rsquo

cad par les plaquettes

THROMBOPOIETINE

APPLICATION

CLINIQUE DE LA

THROMBOPOIETINE

1 rh-TPO deacuteception

2 Dosage ITP hellip

3 Analogues TPO Nplatereg (Romiplostim)

et Revoladereg (Eltrombopag) PTI

4 Production in vitro de plaquettes

Platelet production in vitro

CD34 + cells

Platelets

7-14 days

D 14

D 14

GP-IIbIIIa

D 14

GP-IIIa

CD34Forward vs side

Scatter (d14)

Cells

0

2000000

4000000

6000000

J0 J3 J7 J10 J14

Platelets

0

200000000

400000000

600000000

800000000

1000000000

J0 J3 J7 J10 J14

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

IL-1α induces thrombopoiesis through megakaryocyte rupture in response to

acute platelet needs

Nishimura S1 Nagasaki M2 Kunishima S3 Sawaguchi A4 Sakata A5 Sakaguchi H6

Ohmori T5 Manabe I7 Italiano JE Jr8 Ryu T9 Takayama N10 Komuro I2

Kadowaki T2 Eto K11 Nagai R5

J Cell Biol 2015 May 11209(3)453-66

RUPTURE MEGACARYOCYTAIRE

En guise de conclusion

DIAGNOSTIC Drsquo

HYPERPLAQUETTOSE

La production

des

plaquettes sanguines

Jeudis de Fleurus 2016

Prof Christian CHATELAIN

NTHC

Universiteacute de Namur

POLYPLOIDISATION

MECHANISM

Role of cytoskeletton

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

HYDROXYUREA DECREASES

PROLIFERATION

ANAGRELIDE DECREASES

POLYPLOIDIZATION

PSC CFU-MKMegakaryocytes Platelets

HUDROXYUREA

ANAGRELIDE

THERAPY OF ET

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

Do not forget HYPERURICEMIA

(Allopurinol)

What about PLATELET FUNCTIONS

Pathogeny and treatment of

THROMBOCYTHEMIA

UNDERSTANDING

MEGAKARYOCYTOPOIESIS

2004

Prof Christian CHATELAIN

UCL MONT-GODINNE

HYPERPLAQUETTOSE

REACTIONNELLE vs PRIMITIVE

Effort stress adreacutenaline

Infection inflamation

Carence en fer

Cancer

Vincristine

Aspleacutenie

SMP

LMCTE

Vaquez

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

1975 CFU-MK (Metcalf)

Hieacuterarchie cellulaire

PSC CFU-MKMeacutegacaryocytes Plaquettes

PSC CFU-MKMeacutegacaryocytes Plaquettes

IL-3 GM-CSF

LITHIUM ACETYLCHOLINE

CYCLOSPORINE A

lt 1050

LD-CFU-MK

lt 1050

LD-CFU-MK

PSC

CFU-MK Meacutegacaryocytes Plaquettes

LD-CFU-MK

TPO

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMegakaryocytes Platelets

IL-3 GM-CSF

IL-6 IL-11 LIF

Oncostatin M hellip

1983 Cytokines (Metcalf Quesenberryhellip)

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMeacutegacaryocytes Plaquettes

THROMBOPOIETINE

1994 THROMBOPOIETINE (mpl ligand)

THROMBOPOIETINE

1 mpl oncogene

2 Production constante

3 Stimulates proliferation

4 Controcircle POLYPLOIDISATION

5 LD-CFU-MK

6 Reacutegulation lsquo par produit final rsquo

cad par les plaquettes

THROMBOPOIETINE

APPLICATION

CLINIQUE DE LA

THROMBOPOIETINE

1 rh-TPO deacuteception

2 Dosage ITP hellip

3 Analogues TPO Nplatereg (Romiplostim)

et Revoladereg (Eltrombopag) PTI

4 Production in vitro de plaquettes

Platelet production in vitro

CD34 + cells

Platelets

7-14 days

D 14

D 14

GP-IIbIIIa

D 14

GP-IIIa

CD34Forward vs side

Scatter (d14)

Cells

0

2000000

4000000

6000000

J0 J3 J7 J10 J14

Platelets

0

200000000

400000000

600000000

800000000

1000000000

J0 J3 J7 J10 J14

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

IL-1α induces thrombopoiesis through megakaryocyte rupture in response to

acute platelet needs

Nishimura S1 Nagasaki M2 Kunishima S3 Sawaguchi A4 Sakata A5 Sakaguchi H6

Ohmori T5 Manabe I7 Italiano JE Jr8 Ryu T9 Takayama N10 Komuro I2

Kadowaki T2 Eto K11 Nagai R5

J Cell Biol 2015 May 11209(3)453-66

RUPTURE MEGACARYOCYTAIRE

En guise de conclusion

DIAGNOSTIC Drsquo

HYPERPLAQUETTOSE

La production

des

plaquettes sanguines

Jeudis de Fleurus 2016

Prof Christian CHATELAIN

NTHC

Universiteacute de Namur

POLYPLOIDISATION

MECHANISM

Role of cytoskeletton

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

HYDROXYUREA DECREASES

PROLIFERATION

ANAGRELIDE DECREASES

POLYPLOIDIZATION

PSC CFU-MKMegakaryocytes Platelets

HUDROXYUREA

ANAGRELIDE

THERAPY OF ET

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

Do not forget HYPERURICEMIA

(Allopurinol)

What about PLATELET FUNCTIONS

Pathogeny and treatment of

THROMBOCYTHEMIA

UNDERSTANDING

MEGAKARYOCYTOPOIESIS

2004

Prof Christian CHATELAIN

UCL MONT-GODINNE

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

1975 CFU-MK (Metcalf)

Hieacuterarchie cellulaire

PSC CFU-MKMeacutegacaryocytes Plaquettes

PSC CFU-MKMeacutegacaryocytes Plaquettes

IL-3 GM-CSF

LITHIUM ACETYLCHOLINE

CYCLOSPORINE A

lt 1050

LD-CFU-MK

lt 1050

LD-CFU-MK

PSC

CFU-MK Meacutegacaryocytes Plaquettes

LD-CFU-MK

TPO

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMegakaryocytes Platelets

IL-3 GM-CSF

IL-6 IL-11 LIF

Oncostatin M hellip

1983 Cytokines (Metcalf Quesenberryhellip)

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMeacutegacaryocytes Plaquettes

THROMBOPOIETINE

1994 THROMBOPOIETINE (mpl ligand)

THROMBOPOIETINE

1 mpl oncogene

2 Production constante

3 Stimulates proliferation

4 Controcircle POLYPLOIDISATION

5 LD-CFU-MK

6 Reacutegulation lsquo par produit final rsquo

cad par les plaquettes

THROMBOPOIETINE

APPLICATION

CLINIQUE DE LA

THROMBOPOIETINE

1 rh-TPO deacuteception

2 Dosage ITP hellip

3 Analogues TPO Nplatereg (Romiplostim)

et Revoladereg (Eltrombopag) PTI

4 Production in vitro de plaquettes

Platelet production in vitro

CD34 + cells

Platelets

7-14 days

D 14

D 14

GP-IIbIIIa

D 14

GP-IIIa

CD34Forward vs side

Scatter (d14)

Cells

0

2000000

4000000

6000000

J0 J3 J7 J10 J14

Platelets

0

200000000

400000000

600000000

800000000

1000000000

J0 J3 J7 J10 J14

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

IL-1α induces thrombopoiesis through megakaryocyte rupture in response to

acute platelet needs

Nishimura S1 Nagasaki M2 Kunishima S3 Sawaguchi A4 Sakata A5 Sakaguchi H6

Ohmori T5 Manabe I7 Italiano JE Jr8 Ryu T9 Takayama N10 Komuro I2

Kadowaki T2 Eto K11 Nagai R5

J Cell Biol 2015 May 11209(3)453-66

RUPTURE MEGACARYOCYTAIRE

En guise de conclusion

DIAGNOSTIC Drsquo

HYPERPLAQUETTOSE

La production

des

plaquettes sanguines

Jeudis de Fleurus 2016

Prof Christian CHATELAIN

NTHC

Universiteacute de Namur

POLYPLOIDISATION

MECHANISM

Role of cytoskeletton

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

HYDROXYUREA DECREASES

PROLIFERATION

ANAGRELIDE DECREASES

POLYPLOIDIZATION

PSC CFU-MKMegakaryocytes Platelets

HUDROXYUREA

ANAGRELIDE

THERAPY OF ET

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

Do not forget HYPERURICEMIA

(Allopurinol)

What about PLATELET FUNCTIONS

Pathogeny and treatment of

THROMBOCYTHEMIA

UNDERSTANDING

MEGAKARYOCYTOPOIESIS

2004

Prof Christian CHATELAIN

UCL MONT-GODINNE

1975 CFU-MK (Metcalf)

Hieacuterarchie cellulaire

PSC CFU-MKMeacutegacaryocytes Plaquettes

PSC CFU-MKMeacutegacaryocytes Plaquettes

IL-3 GM-CSF

LITHIUM ACETYLCHOLINE

CYCLOSPORINE A

lt 1050

LD-CFU-MK

lt 1050

LD-CFU-MK

PSC

CFU-MK Meacutegacaryocytes Plaquettes

LD-CFU-MK

TPO

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMegakaryocytes Platelets

IL-3 GM-CSF

IL-6 IL-11 LIF

Oncostatin M hellip

1983 Cytokines (Metcalf Quesenberryhellip)

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMeacutegacaryocytes Plaquettes

THROMBOPOIETINE

1994 THROMBOPOIETINE (mpl ligand)

THROMBOPOIETINE

1 mpl oncogene

2 Production constante

3 Stimulates proliferation

4 Controcircle POLYPLOIDISATION

5 LD-CFU-MK

6 Reacutegulation lsquo par produit final rsquo

cad par les plaquettes

THROMBOPOIETINE

APPLICATION

CLINIQUE DE LA

THROMBOPOIETINE

1 rh-TPO deacuteception

2 Dosage ITP hellip

3 Analogues TPO Nplatereg (Romiplostim)

et Revoladereg (Eltrombopag) PTI

4 Production in vitro de plaquettes

Platelet production in vitro

CD34 + cells

Platelets

7-14 days

D 14

D 14

GP-IIbIIIa

D 14

GP-IIIa

CD34Forward vs side

Scatter (d14)

Cells

0

2000000

4000000

6000000

J0 J3 J7 J10 J14

Platelets

0

200000000

400000000

600000000

800000000

1000000000

J0 J3 J7 J10 J14

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

IL-1α induces thrombopoiesis through megakaryocyte rupture in response to

acute platelet needs

Nishimura S1 Nagasaki M2 Kunishima S3 Sawaguchi A4 Sakata A5 Sakaguchi H6

Ohmori T5 Manabe I7 Italiano JE Jr8 Ryu T9 Takayama N10 Komuro I2

Kadowaki T2 Eto K11 Nagai R5

J Cell Biol 2015 May 11209(3)453-66

RUPTURE MEGACARYOCYTAIRE

En guise de conclusion

DIAGNOSTIC Drsquo

HYPERPLAQUETTOSE

La production

des

plaquettes sanguines

Jeudis de Fleurus 2016

Prof Christian CHATELAIN

NTHC

Universiteacute de Namur

POLYPLOIDISATION

MECHANISM

Role of cytoskeletton

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

HYDROXYUREA DECREASES

PROLIFERATION

ANAGRELIDE DECREASES

POLYPLOIDIZATION

PSC CFU-MKMegakaryocytes Platelets

HUDROXYUREA

ANAGRELIDE

THERAPY OF ET

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

Do not forget HYPERURICEMIA

(Allopurinol)

What about PLATELET FUNCTIONS

Pathogeny and treatment of

THROMBOCYTHEMIA

UNDERSTANDING

MEGAKARYOCYTOPOIESIS

2004

Prof Christian CHATELAIN

UCL MONT-GODINNE

Hieacuterarchie cellulaire

PSC CFU-MKMeacutegacaryocytes Plaquettes

PSC CFU-MKMeacutegacaryocytes Plaquettes

IL-3 GM-CSF

LITHIUM ACETYLCHOLINE

CYCLOSPORINE A

lt 1050

LD-CFU-MK

lt 1050

LD-CFU-MK

PSC

CFU-MK Meacutegacaryocytes Plaquettes

LD-CFU-MK

TPO

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMegakaryocytes Platelets

IL-3 GM-CSF

IL-6 IL-11 LIF

Oncostatin M hellip

1983 Cytokines (Metcalf Quesenberryhellip)

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMeacutegacaryocytes Plaquettes

THROMBOPOIETINE

1994 THROMBOPOIETINE (mpl ligand)

THROMBOPOIETINE

1 mpl oncogene

2 Production constante

3 Stimulates proliferation

4 Controcircle POLYPLOIDISATION

5 LD-CFU-MK

6 Reacutegulation lsquo par produit final rsquo

cad par les plaquettes

THROMBOPOIETINE

APPLICATION

CLINIQUE DE LA

THROMBOPOIETINE

1 rh-TPO deacuteception

2 Dosage ITP hellip

3 Analogues TPO Nplatereg (Romiplostim)

et Revoladereg (Eltrombopag) PTI

4 Production in vitro de plaquettes

Platelet production in vitro

CD34 + cells

Platelets

7-14 days

D 14

D 14

GP-IIbIIIa

D 14

GP-IIIa

CD34Forward vs side

Scatter (d14)

Cells

0

2000000

4000000

6000000

J0 J3 J7 J10 J14

Platelets

0

200000000

400000000

600000000

800000000

1000000000

J0 J3 J7 J10 J14

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

IL-1α induces thrombopoiesis through megakaryocyte rupture in response to

acute platelet needs

Nishimura S1 Nagasaki M2 Kunishima S3 Sawaguchi A4 Sakata A5 Sakaguchi H6

Ohmori T5 Manabe I7 Italiano JE Jr8 Ryu T9 Takayama N10 Komuro I2

Kadowaki T2 Eto K11 Nagai R5

J Cell Biol 2015 May 11209(3)453-66

RUPTURE MEGACARYOCYTAIRE

En guise de conclusion

DIAGNOSTIC Drsquo

HYPERPLAQUETTOSE

La production

des

plaquettes sanguines

Jeudis de Fleurus 2016

Prof Christian CHATELAIN

NTHC

Universiteacute de Namur

POLYPLOIDISATION

MECHANISM

Role of cytoskeletton

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

HYDROXYUREA DECREASES

PROLIFERATION

ANAGRELIDE DECREASES

POLYPLOIDIZATION

PSC CFU-MKMegakaryocytes Platelets

HUDROXYUREA

ANAGRELIDE

THERAPY OF ET

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

Do not forget HYPERURICEMIA

(Allopurinol)

What about PLATELET FUNCTIONS

Pathogeny and treatment of

THROMBOCYTHEMIA

UNDERSTANDING

MEGAKARYOCYTOPOIESIS

2004

Prof Christian CHATELAIN

UCL MONT-GODINNE

PSC CFU-MKMeacutegacaryocytes Plaquettes

IL-3 GM-CSF

LITHIUM ACETYLCHOLINE

CYCLOSPORINE A

lt 1050

LD-CFU-MK

lt 1050

LD-CFU-MK

PSC

CFU-MK Meacutegacaryocytes Plaquettes

LD-CFU-MK

TPO

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMegakaryocytes Platelets

IL-3 GM-CSF

IL-6 IL-11 LIF

Oncostatin M hellip

1983 Cytokines (Metcalf Quesenberryhellip)

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMeacutegacaryocytes Plaquettes

THROMBOPOIETINE

1994 THROMBOPOIETINE (mpl ligand)

THROMBOPOIETINE

1 mpl oncogene

2 Production constante

3 Stimulates proliferation

4 Controcircle POLYPLOIDISATION

5 LD-CFU-MK

6 Reacutegulation lsquo par produit final rsquo

cad par les plaquettes

THROMBOPOIETINE

APPLICATION

CLINIQUE DE LA

THROMBOPOIETINE

1 rh-TPO deacuteception

2 Dosage ITP hellip

3 Analogues TPO Nplatereg (Romiplostim)

et Revoladereg (Eltrombopag) PTI

4 Production in vitro de plaquettes

Platelet production in vitro

CD34 + cells

Platelets

7-14 days

D 14

D 14

GP-IIbIIIa

D 14

GP-IIIa

CD34Forward vs side

Scatter (d14)

Cells

0

2000000

4000000

6000000

J0 J3 J7 J10 J14

Platelets

0

200000000

400000000

600000000

800000000

1000000000

J0 J3 J7 J10 J14

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

IL-1α induces thrombopoiesis through megakaryocyte rupture in response to

acute platelet needs

Nishimura S1 Nagasaki M2 Kunishima S3 Sawaguchi A4 Sakata A5 Sakaguchi H6

Ohmori T5 Manabe I7 Italiano JE Jr8 Ryu T9 Takayama N10 Komuro I2

Kadowaki T2 Eto K11 Nagai R5

J Cell Biol 2015 May 11209(3)453-66

RUPTURE MEGACARYOCYTAIRE

En guise de conclusion

DIAGNOSTIC Drsquo

HYPERPLAQUETTOSE

La production

des

plaquettes sanguines

Jeudis de Fleurus 2016

Prof Christian CHATELAIN

NTHC

Universiteacute de Namur

POLYPLOIDISATION

MECHANISM

Role of cytoskeletton

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

HYDROXYUREA DECREASES

PROLIFERATION

ANAGRELIDE DECREASES

POLYPLOIDIZATION

PSC CFU-MKMegakaryocytes Platelets

HUDROXYUREA

ANAGRELIDE

THERAPY OF ET

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

Do not forget HYPERURICEMIA

(Allopurinol)

What about PLATELET FUNCTIONS

Pathogeny and treatment of

THROMBOCYTHEMIA

UNDERSTANDING

MEGAKARYOCYTOPOIESIS

2004

Prof Christian CHATELAIN

UCL MONT-GODINNE

lt 1050

LD-CFU-MK

lt 1050

LD-CFU-MK

PSC

CFU-MK Meacutegacaryocytes Plaquettes

LD-CFU-MK

TPO

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMegakaryocytes Platelets

IL-3 GM-CSF

IL-6 IL-11 LIF

Oncostatin M hellip

1983 Cytokines (Metcalf Quesenberryhellip)

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMeacutegacaryocytes Plaquettes

THROMBOPOIETINE

1994 THROMBOPOIETINE (mpl ligand)

THROMBOPOIETINE

1 mpl oncogene

2 Production constante

3 Stimulates proliferation

4 Controcircle POLYPLOIDISATION

5 LD-CFU-MK

6 Reacutegulation lsquo par produit final rsquo

cad par les plaquettes

THROMBOPOIETINE

APPLICATION

CLINIQUE DE LA

THROMBOPOIETINE

1 rh-TPO deacuteception

2 Dosage ITP hellip

3 Analogues TPO Nplatereg (Romiplostim)

et Revoladereg (Eltrombopag) PTI

4 Production in vitro de plaquettes

Platelet production in vitro

CD34 + cells

Platelets

7-14 days

D 14

D 14

GP-IIbIIIa

D 14

GP-IIIa

CD34Forward vs side

Scatter (d14)

Cells

0

2000000

4000000

6000000

J0 J3 J7 J10 J14

Platelets

0

200000000

400000000

600000000

800000000

1000000000

J0 J3 J7 J10 J14

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

IL-1α induces thrombopoiesis through megakaryocyte rupture in response to

acute platelet needs

Nishimura S1 Nagasaki M2 Kunishima S3 Sawaguchi A4 Sakata A5 Sakaguchi H6

Ohmori T5 Manabe I7 Italiano JE Jr8 Ryu T9 Takayama N10 Komuro I2

Kadowaki T2 Eto K11 Nagai R5

J Cell Biol 2015 May 11209(3)453-66

RUPTURE MEGACARYOCYTAIRE

En guise de conclusion

DIAGNOSTIC Drsquo

HYPERPLAQUETTOSE

La production

des

plaquettes sanguines

Jeudis de Fleurus 2016

Prof Christian CHATELAIN

NTHC

Universiteacute de Namur

POLYPLOIDISATION

MECHANISM

Role of cytoskeletton

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

HYDROXYUREA DECREASES

PROLIFERATION

ANAGRELIDE DECREASES

POLYPLOIDIZATION

PSC CFU-MKMegakaryocytes Platelets

HUDROXYUREA

ANAGRELIDE

THERAPY OF ET

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

Do not forget HYPERURICEMIA

(Allopurinol)

What about PLATELET FUNCTIONS

Pathogeny and treatment of

THROMBOCYTHEMIA

UNDERSTANDING

MEGAKARYOCYTOPOIESIS

2004

Prof Christian CHATELAIN

UCL MONT-GODINNE

lt 1050

LD-CFU-MK

PSC

CFU-MK Meacutegacaryocytes Plaquettes

LD-CFU-MK

TPO

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMegakaryocytes Platelets

IL-3 GM-CSF

IL-6 IL-11 LIF

Oncostatin M hellip

1983 Cytokines (Metcalf Quesenberryhellip)

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMeacutegacaryocytes Plaquettes

THROMBOPOIETINE

1994 THROMBOPOIETINE (mpl ligand)

THROMBOPOIETINE

1 mpl oncogene

2 Production constante

3 Stimulates proliferation

4 Controcircle POLYPLOIDISATION

5 LD-CFU-MK

6 Reacutegulation lsquo par produit final rsquo

cad par les plaquettes

THROMBOPOIETINE

APPLICATION

CLINIQUE DE LA

THROMBOPOIETINE

1 rh-TPO deacuteception

2 Dosage ITP hellip

3 Analogues TPO Nplatereg (Romiplostim)

et Revoladereg (Eltrombopag) PTI

4 Production in vitro de plaquettes

Platelet production in vitro

CD34 + cells

Platelets

7-14 days

D 14

D 14

GP-IIbIIIa

D 14

GP-IIIa

CD34Forward vs side

Scatter (d14)

Cells

0

2000000

4000000

6000000

J0 J3 J7 J10 J14

Platelets

0

200000000

400000000

600000000

800000000

1000000000

J0 J3 J7 J10 J14

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

IL-1α induces thrombopoiesis through megakaryocyte rupture in response to

acute platelet needs

Nishimura S1 Nagasaki M2 Kunishima S3 Sawaguchi A4 Sakata A5 Sakaguchi H6

Ohmori T5 Manabe I7 Italiano JE Jr8 Ryu T9 Takayama N10 Komuro I2

Kadowaki T2 Eto K11 Nagai R5

J Cell Biol 2015 May 11209(3)453-66

RUPTURE MEGACARYOCYTAIRE

En guise de conclusion

DIAGNOSTIC Drsquo

HYPERPLAQUETTOSE

La production

des

plaquettes sanguines

Jeudis de Fleurus 2016

Prof Christian CHATELAIN

NTHC

Universiteacute de Namur

POLYPLOIDISATION

MECHANISM

Role of cytoskeletton

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

HYDROXYUREA DECREASES

PROLIFERATION

ANAGRELIDE DECREASES

POLYPLOIDIZATION

PSC CFU-MKMegakaryocytes Platelets

HUDROXYUREA

ANAGRELIDE

THERAPY OF ET

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

Do not forget HYPERURICEMIA

(Allopurinol)

What about PLATELET FUNCTIONS

Pathogeny and treatment of

THROMBOCYTHEMIA

UNDERSTANDING

MEGAKARYOCYTOPOIESIS

2004

Prof Christian CHATELAIN

UCL MONT-GODINNE

PSC

CFU-MK Meacutegacaryocytes Plaquettes

LD-CFU-MK

TPO

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMegakaryocytes Platelets

IL-3 GM-CSF

IL-6 IL-11 LIF

Oncostatin M hellip

1983 Cytokines (Metcalf Quesenberryhellip)

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMeacutegacaryocytes Plaquettes

THROMBOPOIETINE

1994 THROMBOPOIETINE (mpl ligand)

THROMBOPOIETINE

1 mpl oncogene

2 Production constante

3 Stimulates proliferation

4 Controcircle POLYPLOIDISATION

5 LD-CFU-MK

6 Reacutegulation lsquo par produit final rsquo

cad par les plaquettes

THROMBOPOIETINE

APPLICATION

CLINIQUE DE LA

THROMBOPOIETINE

1 rh-TPO deacuteception

2 Dosage ITP hellip

3 Analogues TPO Nplatereg (Romiplostim)

et Revoladereg (Eltrombopag) PTI

4 Production in vitro de plaquettes

Platelet production in vitro

CD34 + cells

Platelets

7-14 days

D 14

D 14

GP-IIbIIIa

D 14

GP-IIIa

CD34Forward vs side

Scatter (d14)

Cells

0

2000000

4000000

6000000

J0 J3 J7 J10 J14

Platelets

0

200000000

400000000

600000000

800000000

1000000000

J0 J3 J7 J10 J14

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

IL-1α induces thrombopoiesis through megakaryocyte rupture in response to

acute platelet needs

Nishimura S1 Nagasaki M2 Kunishima S3 Sawaguchi A4 Sakata A5 Sakaguchi H6

Ohmori T5 Manabe I7 Italiano JE Jr8 Ryu T9 Takayama N10 Komuro I2

Kadowaki T2 Eto K11 Nagai R5

J Cell Biol 2015 May 11209(3)453-66

RUPTURE MEGACARYOCYTAIRE

En guise de conclusion

DIAGNOSTIC Drsquo

HYPERPLAQUETTOSE

La production

des

plaquettes sanguines

Jeudis de Fleurus 2016

Prof Christian CHATELAIN

NTHC

Universiteacute de Namur

POLYPLOIDISATION

MECHANISM

Role of cytoskeletton

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

HYDROXYUREA DECREASES

PROLIFERATION

ANAGRELIDE DECREASES

POLYPLOIDIZATION

PSC CFU-MKMegakaryocytes Platelets

HUDROXYUREA

ANAGRELIDE

THERAPY OF ET

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

Do not forget HYPERURICEMIA

(Allopurinol)

What about PLATELET FUNCTIONS

Pathogeny and treatment of

THROMBOCYTHEMIA

UNDERSTANDING

MEGAKARYOCYTOPOIESIS

2004

Prof Christian CHATELAIN

UCL MONT-GODINNE

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMegakaryocytes Platelets

IL-3 GM-CSF

IL-6 IL-11 LIF

Oncostatin M hellip

1983 Cytokines (Metcalf Quesenberryhellip)

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMeacutegacaryocytes Plaquettes

THROMBOPOIETINE

1994 THROMBOPOIETINE (mpl ligand)

THROMBOPOIETINE

1 mpl oncogene

2 Production constante

3 Stimulates proliferation

4 Controcircle POLYPLOIDISATION

5 LD-CFU-MK

6 Reacutegulation lsquo par produit final rsquo

cad par les plaquettes

THROMBOPOIETINE

APPLICATION

CLINIQUE DE LA

THROMBOPOIETINE

1 rh-TPO deacuteception

2 Dosage ITP hellip

3 Analogues TPO Nplatereg (Romiplostim)

et Revoladereg (Eltrombopag) PTI

4 Production in vitro de plaquettes

Platelet production in vitro

CD34 + cells

Platelets

7-14 days

D 14

D 14

GP-IIbIIIa

D 14

GP-IIIa

CD34Forward vs side

Scatter (d14)

Cells

0

2000000

4000000

6000000

J0 J3 J7 J10 J14

Platelets

0

200000000

400000000

600000000

800000000

1000000000

J0 J3 J7 J10 J14

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

IL-1α induces thrombopoiesis through megakaryocyte rupture in response to

acute platelet needs

Nishimura S1 Nagasaki M2 Kunishima S3 Sawaguchi A4 Sakata A5 Sakaguchi H6

Ohmori T5 Manabe I7 Italiano JE Jr8 Ryu T9 Takayama N10 Komuro I2

Kadowaki T2 Eto K11 Nagai R5

J Cell Biol 2015 May 11209(3)453-66

RUPTURE MEGACARYOCYTAIRE

En guise de conclusion

DIAGNOSTIC Drsquo

HYPERPLAQUETTOSE

La production

des

plaquettes sanguines

Jeudis de Fleurus 2016

Prof Christian CHATELAIN

NTHC

Universiteacute de Namur

POLYPLOIDISATION

MECHANISM

Role of cytoskeletton

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

HYDROXYUREA DECREASES

PROLIFERATION

ANAGRELIDE DECREASES

POLYPLOIDIZATION

PSC CFU-MKMegakaryocytes Platelets

HUDROXYUREA

ANAGRELIDE

THERAPY OF ET

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

Do not forget HYPERURICEMIA

(Allopurinol)

What about PLATELET FUNCTIONS

Pathogeny and treatment of

THROMBOCYTHEMIA

UNDERSTANDING

MEGAKARYOCYTOPOIESIS

2004

Prof Christian CHATELAIN

UCL MONT-GODINNE

PSC CFU-MKMegakaryocytes Platelets

IL-3 GM-CSF

IL-6 IL-11 LIF

Oncostatin M hellip

1983 Cytokines (Metcalf Quesenberryhellip)

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMeacutegacaryocytes Plaquettes

THROMBOPOIETINE

1994 THROMBOPOIETINE (mpl ligand)

THROMBOPOIETINE

1 mpl oncogene

2 Production constante

3 Stimulates proliferation

4 Controcircle POLYPLOIDISATION

5 LD-CFU-MK

6 Reacutegulation lsquo par produit final rsquo

cad par les plaquettes

THROMBOPOIETINE

APPLICATION

CLINIQUE DE LA

THROMBOPOIETINE

1 rh-TPO deacuteception

2 Dosage ITP hellip

3 Analogues TPO Nplatereg (Romiplostim)

et Revoladereg (Eltrombopag) PTI

4 Production in vitro de plaquettes

Platelet production in vitro

CD34 + cells

Platelets

7-14 days

D 14

D 14

GP-IIbIIIa

D 14

GP-IIIa

CD34Forward vs side

Scatter (d14)

Cells

0

2000000

4000000

6000000

J0 J3 J7 J10 J14

Platelets

0

200000000

400000000

600000000

800000000

1000000000

J0 J3 J7 J10 J14

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

IL-1α induces thrombopoiesis through megakaryocyte rupture in response to

acute platelet needs

Nishimura S1 Nagasaki M2 Kunishima S3 Sawaguchi A4 Sakata A5 Sakaguchi H6

Ohmori T5 Manabe I7 Italiano JE Jr8 Ryu T9 Takayama N10 Komuro I2

Kadowaki T2 Eto K11 Nagai R5

J Cell Biol 2015 May 11209(3)453-66

RUPTURE MEGACARYOCYTAIRE

En guise de conclusion

DIAGNOSTIC Drsquo

HYPERPLAQUETTOSE

La production

des

plaquettes sanguines

Jeudis de Fleurus 2016

Prof Christian CHATELAIN

NTHC

Universiteacute de Namur

POLYPLOIDISATION

MECHANISM

Role of cytoskeletton

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

HYDROXYUREA DECREASES

PROLIFERATION

ANAGRELIDE DECREASES

POLYPLOIDIZATION

PSC CFU-MKMegakaryocytes Platelets

HUDROXYUREA

ANAGRELIDE

THERAPY OF ET

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

Do not forget HYPERURICEMIA

(Allopurinol)

What about PLATELET FUNCTIONS

Pathogeny and treatment of

THROMBOCYTHEMIA

UNDERSTANDING

MEGAKARYOCYTOPOIESIS

2004

Prof Christian CHATELAIN

UCL MONT-GODINNE

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

PSC CFU-MKMeacutegacaryocytes Plaquettes

THROMBOPOIETINE

1994 THROMBOPOIETINE (mpl ligand)

THROMBOPOIETINE

1 mpl oncogene

2 Production constante

3 Stimulates proliferation

4 Controcircle POLYPLOIDISATION

5 LD-CFU-MK

6 Reacutegulation lsquo par produit final rsquo

cad par les plaquettes

THROMBOPOIETINE

APPLICATION

CLINIQUE DE LA

THROMBOPOIETINE

1 rh-TPO deacuteception

2 Dosage ITP hellip

3 Analogues TPO Nplatereg (Romiplostim)

et Revoladereg (Eltrombopag) PTI

4 Production in vitro de plaquettes

Platelet production in vitro

CD34 + cells

Platelets

7-14 days

D 14

D 14

GP-IIbIIIa

D 14

GP-IIIa

CD34Forward vs side

Scatter (d14)

Cells

0

2000000

4000000

6000000

J0 J3 J7 J10 J14

Platelets

0

200000000

400000000

600000000

800000000

1000000000

J0 J3 J7 J10 J14

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

IL-1α induces thrombopoiesis through megakaryocyte rupture in response to

acute platelet needs

Nishimura S1 Nagasaki M2 Kunishima S3 Sawaguchi A4 Sakata A5 Sakaguchi H6

Ohmori T5 Manabe I7 Italiano JE Jr8 Ryu T9 Takayama N10 Komuro I2

Kadowaki T2 Eto K11 Nagai R5

J Cell Biol 2015 May 11209(3)453-66

RUPTURE MEGACARYOCYTAIRE

En guise de conclusion

DIAGNOSTIC Drsquo

HYPERPLAQUETTOSE

La production

des

plaquettes sanguines

Jeudis de Fleurus 2016

Prof Christian CHATELAIN

NTHC

Universiteacute de Namur

POLYPLOIDISATION

MECHANISM

Role of cytoskeletton

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

HYDROXYUREA DECREASES

PROLIFERATION

ANAGRELIDE DECREASES

POLYPLOIDIZATION

PSC CFU-MKMegakaryocytes Platelets

HUDROXYUREA

ANAGRELIDE

THERAPY OF ET

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

Do not forget HYPERURICEMIA

(Allopurinol)

What about PLATELET FUNCTIONS

Pathogeny and treatment of

THROMBOCYTHEMIA

UNDERSTANDING

MEGAKARYOCYTOPOIESIS

2004

Prof Christian CHATELAIN

UCL MONT-GODINNE

PSC CFU-MKMeacutegacaryocytes Plaquettes

THROMBOPOIETINE

1994 THROMBOPOIETINE (mpl ligand)

THROMBOPOIETINE

1 mpl oncogene

2 Production constante

3 Stimulates proliferation

4 Controcircle POLYPLOIDISATION

5 LD-CFU-MK

6 Reacutegulation lsquo par produit final rsquo

cad par les plaquettes

THROMBOPOIETINE

APPLICATION

CLINIQUE DE LA

THROMBOPOIETINE

1 rh-TPO deacuteception

2 Dosage ITP hellip

3 Analogues TPO Nplatereg (Romiplostim)

et Revoladereg (Eltrombopag) PTI

4 Production in vitro de plaquettes

Platelet production in vitro

CD34 + cells

Platelets

7-14 days

D 14

D 14

GP-IIbIIIa

D 14

GP-IIIa

CD34Forward vs side

Scatter (d14)

Cells

0

2000000

4000000

6000000

J0 J3 J7 J10 J14

Platelets

0

200000000

400000000

600000000

800000000

1000000000

J0 J3 J7 J10 J14

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

IL-1α induces thrombopoiesis through megakaryocyte rupture in response to

acute platelet needs

Nishimura S1 Nagasaki M2 Kunishima S3 Sawaguchi A4 Sakata A5 Sakaguchi H6

Ohmori T5 Manabe I7 Italiano JE Jr8 Ryu T9 Takayama N10 Komuro I2

Kadowaki T2 Eto K11 Nagai R5

J Cell Biol 2015 May 11209(3)453-66

RUPTURE MEGACARYOCYTAIRE

En guise de conclusion

DIAGNOSTIC Drsquo

HYPERPLAQUETTOSE

La production

des

plaquettes sanguines

Jeudis de Fleurus 2016

Prof Christian CHATELAIN

NTHC

Universiteacute de Namur

POLYPLOIDISATION

MECHANISM

Role of cytoskeletton

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

HYDROXYUREA DECREASES

PROLIFERATION

ANAGRELIDE DECREASES

POLYPLOIDIZATION

PSC CFU-MKMegakaryocytes Platelets

HUDROXYUREA

ANAGRELIDE

THERAPY OF ET

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

Do not forget HYPERURICEMIA

(Allopurinol)

What about PLATELET FUNCTIONS

Pathogeny and treatment of

THROMBOCYTHEMIA

UNDERSTANDING

MEGAKARYOCYTOPOIESIS

2004

Prof Christian CHATELAIN

UCL MONT-GODINNE

THROMBOPOIETINE

1 mpl oncogene

2 Production constante

3 Stimulates proliferation

4 Controcircle POLYPLOIDISATION

5 LD-CFU-MK

6 Reacutegulation lsquo par produit final rsquo

cad par les plaquettes

THROMBOPOIETINE

APPLICATION

CLINIQUE DE LA

THROMBOPOIETINE

1 rh-TPO deacuteception

2 Dosage ITP hellip

3 Analogues TPO Nplatereg (Romiplostim)

et Revoladereg (Eltrombopag) PTI

4 Production in vitro de plaquettes

Platelet production in vitro

CD34 + cells

Platelets

7-14 days

D 14

D 14

GP-IIbIIIa

D 14

GP-IIIa

CD34Forward vs side

Scatter (d14)

Cells

0

2000000

4000000

6000000

J0 J3 J7 J10 J14

Platelets

0

200000000

400000000

600000000

800000000

1000000000

J0 J3 J7 J10 J14

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

IL-1α induces thrombopoiesis through megakaryocyte rupture in response to

acute platelet needs

Nishimura S1 Nagasaki M2 Kunishima S3 Sawaguchi A4 Sakata A5 Sakaguchi H6

Ohmori T5 Manabe I7 Italiano JE Jr8 Ryu T9 Takayama N10 Komuro I2

Kadowaki T2 Eto K11 Nagai R5

J Cell Biol 2015 May 11209(3)453-66

RUPTURE MEGACARYOCYTAIRE

En guise de conclusion

DIAGNOSTIC Drsquo

HYPERPLAQUETTOSE

La production

des

plaquettes sanguines

Jeudis de Fleurus 2016

Prof Christian CHATELAIN

NTHC

Universiteacute de Namur

POLYPLOIDISATION

MECHANISM

Role of cytoskeletton

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

HYDROXYUREA DECREASES

PROLIFERATION

ANAGRELIDE DECREASES

POLYPLOIDIZATION

PSC CFU-MKMegakaryocytes Platelets

HUDROXYUREA

ANAGRELIDE

THERAPY OF ET

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

Do not forget HYPERURICEMIA

(Allopurinol)

What about PLATELET FUNCTIONS

Pathogeny and treatment of

THROMBOCYTHEMIA

UNDERSTANDING

MEGAKARYOCYTOPOIESIS

2004

Prof Christian CHATELAIN

UCL MONT-GODINNE

THROMBOPOIETINE

APPLICATION

CLINIQUE DE LA

THROMBOPOIETINE

1 rh-TPO deacuteception

2 Dosage ITP hellip

3 Analogues TPO Nplatereg (Romiplostim)

et Revoladereg (Eltrombopag) PTI

4 Production in vitro de plaquettes

Platelet production in vitro

CD34 + cells

Platelets

7-14 days

D 14

D 14

GP-IIbIIIa

D 14

GP-IIIa

CD34Forward vs side

Scatter (d14)

Cells

0

2000000

4000000

6000000

J0 J3 J7 J10 J14

Platelets

0

200000000

400000000

600000000

800000000

1000000000

J0 J3 J7 J10 J14

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

IL-1α induces thrombopoiesis through megakaryocyte rupture in response to

acute platelet needs

Nishimura S1 Nagasaki M2 Kunishima S3 Sawaguchi A4 Sakata A5 Sakaguchi H6

Ohmori T5 Manabe I7 Italiano JE Jr8 Ryu T9 Takayama N10 Komuro I2

Kadowaki T2 Eto K11 Nagai R5

J Cell Biol 2015 May 11209(3)453-66

RUPTURE MEGACARYOCYTAIRE

En guise de conclusion

DIAGNOSTIC Drsquo

HYPERPLAQUETTOSE

La production

des

plaquettes sanguines

Jeudis de Fleurus 2016

Prof Christian CHATELAIN

NTHC

Universiteacute de Namur

POLYPLOIDISATION

MECHANISM

Role of cytoskeletton

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

HYDROXYUREA DECREASES

PROLIFERATION

ANAGRELIDE DECREASES

POLYPLOIDIZATION

PSC CFU-MKMegakaryocytes Platelets

HUDROXYUREA

ANAGRELIDE

THERAPY OF ET

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

Do not forget HYPERURICEMIA

(Allopurinol)

What about PLATELET FUNCTIONS

Pathogeny and treatment of

THROMBOCYTHEMIA

UNDERSTANDING

MEGAKARYOCYTOPOIESIS

2004

Prof Christian CHATELAIN

UCL MONT-GODINNE

APPLICATION

CLINIQUE DE LA

THROMBOPOIETINE

1 rh-TPO deacuteception

2 Dosage ITP hellip

3 Analogues TPO Nplatereg (Romiplostim)

et Revoladereg (Eltrombopag) PTI

4 Production in vitro de plaquettes

Platelet production in vitro

CD34 + cells

Platelets

7-14 days

D 14

D 14

GP-IIbIIIa

D 14

GP-IIIa

CD34Forward vs side

Scatter (d14)

Cells

0

2000000

4000000

6000000

J0 J3 J7 J10 J14

Platelets

0

200000000

400000000

600000000

800000000

1000000000

J0 J3 J7 J10 J14

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

IL-1α induces thrombopoiesis through megakaryocyte rupture in response to

acute platelet needs

Nishimura S1 Nagasaki M2 Kunishima S3 Sawaguchi A4 Sakata A5 Sakaguchi H6

Ohmori T5 Manabe I7 Italiano JE Jr8 Ryu T9 Takayama N10 Komuro I2

Kadowaki T2 Eto K11 Nagai R5

J Cell Biol 2015 May 11209(3)453-66

RUPTURE MEGACARYOCYTAIRE

En guise de conclusion

DIAGNOSTIC Drsquo

HYPERPLAQUETTOSE

La production

des

plaquettes sanguines

Jeudis de Fleurus 2016

Prof Christian CHATELAIN

NTHC

Universiteacute de Namur

POLYPLOIDISATION

MECHANISM

Role of cytoskeletton

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

HYDROXYUREA DECREASES

PROLIFERATION

ANAGRELIDE DECREASES

POLYPLOIDIZATION

PSC CFU-MKMegakaryocytes Platelets

HUDROXYUREA

ANAGRELIDE

THERAPY OF ET

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

Do not forget HYPERURICEMIA

(Allopurinol)

What about PLATELET FUNCTIONS

Pathogeny and treatment of

THROMBOCYTHEMIA

UNDERSTANDING

MEGAKARYOCYTOPOIESIS

2004

Prof Christian CHATELAIN

UCL MONT-GODINNE

Platelet production in vitro

CD34 + cells

Platelets

7-14 days

D 14

D 14

GP-IIbIIIa

D 14

GP-IIIa

CD34Forward vs side

Scatter (d14)

Cells

0

2000000

4000000

6000000

J0 J3 J7 J10 J14

Platelets

0

200000000

400000000

600000000

800000000

1000000000

J0 J3 J7 J10 J14

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

IL-1α induces thrombopoiesis through megakaryocyte rupture in response to

acute platelet needs

Nishimura S1 Nagasaki M2 Kunishima S3 Sawaguchi A4 Sakata A5 Sakaguchi H6

Ohmori T5 Manabe I7 Italiano JE Jr8 Ryu T9 Takayama N10 Komuro I2

Kadowaki T2 Eto K11 Nagai R5

J Cell Biol 2015 May 11209(3)453-66

RUPTURE MEGACARYOCYTAIRE

En guise de conclusion

DIAGNOSTIC Drsquo

HYPERPLAQUETTOSE

La production

des

plaquettes sanguines

Jeudis de Fleurus 2016

Prof Christian CHATELAIN

NTHC

Universiteacute de Namur

POLYPLOIDISATION

MECHANISM

Role of cytoskeletton

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

HYDROXYUREA DECREASES

PROLIFERATION

ANAGRELIDE DECREASES

POLYPLOIDIZATION

PSC CFU-MKMegakaryocytes Platelets

HUDROXYUREA

ANAGRELIDE

THERAPY OF ET

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

Do not forget HYPERURICEMIA

(Allopurinol)

What about PLATELET FUNCTIONS

Pathogeny and treatment of

THROMBOCYTHEMIA

UNDERSTANDING

MEGAKARYOCYTOPOIESIS

2004

Prof Christian CHATELAIN

UCL MONT-GODINNE

D 14

D 14

GP-IIbIIIa

D 14

GP-IIIa

CD34Forward vs side

Scatter (d14)

Cells

0

2000000

4000000

6000000

J0 J3 J7 J10 J14

Platelets

0

200000000

400000000

600000000

800000000

1000000000

J0 J3 J7 J10 J14

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

IL-1α induces thrombopoiesis through megakaryocyte rupture in response to

acute platelet needs

Nishimura S1 Nagasaki M2 Kunishima S3 Sawaguchi A4 Sakata A5 Sakaguchi H6

Ohmori T5 Manabe I7 Italiano JE Jr8 Ryu T9 Takayama N10 Komuro I2

Kadowaki T2 Eto K11 Nagai R5

J Cell Biol 2015 May 11209(3)453-66

RUPTURE MEGACARYOCYTAIRE

En guise de conclusion

DIAGNOSTIC Drsquo

HYPERPLAQUETTOSE

La production

des

plaquettes sanguines

Jeudis de Fleurus 2016

Prof Christian CHATELAIN

NTHC

Universiteacute de Namur

POLYPLOIDISATION

MECHANISM

Role of cytoskeletton

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

HYDROXYUREA DECREASES

PROLIFERATION

ANAGRELIDE DECREASES

POLYPLOIDIZATION

PSC CFU-MKMegakaryocytes Platelets

HUDROXYUREA

ANAGRELIDE

THERAPY OF ET

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

Do not forget HYPERURICEMIA

(Allopurinol)

What about PLATELET FUNCTIONS

Pathogeny and treatment of

THROMBOCYTHEMIA

UNDERSTANDING

MEGAKARYOCYTOPOIESIS

2004

Prof Christian CHATELAIN

UCL MONT-GODINNE

D 14

GP-IIbIIIa

D 14

GP-IIIa

CD34Forward vs side

Scatter (d14)

Cells

0

2000000

4000000

6000000

J0 J3 J7 J10 J14

Platelets

0

200000000

400000000

600000000

800000000

1000000000

J0 J3 J7 J10 J14

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

IL-1α induces thrombopoiesis through megakaryocyte rupture in response to

acute platelet needs

Nishimura S1 Nagasaki M2 Kunishima S3 Sawaguchi A4 Sakata A5 Sakaguchi H6

Ohmori T5 Manabe I7 Italiano JE Jr8 Ryu T9 Takayama N10 Komuro I2

Kadowaki T2 Eto K11 Nagai R5

J Cell Biol 2015 May 11209(3)453-66

RUPTURE MEGACARYOCYTAIRE

En guise de conclusion

DIAGNOSTIC Drsquo

HYPERPLAQUETTOSE

La production

des

plaquettes sanguines

Jeudis de Fleurus 2016

Prof Christian CHATELAIN

NTHC

Universiteacute de Namur

POLYPLOIDISATION

MECHANISM

Role of cytoskeletton

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

HYDROXYUREA DECREASES

PROLIFERATION

ANAGRELIDE DECREASES

POLYPLOIDIZATION

PSC CFU-MKMegakaryocytes Platelets

HUDROXYUREA

ANAGRELIDE

THERAPY OF ET

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

Do not forget HYPERURICEMIA

(Allopurinol)

What about PLATELET FUNCTIONS

Pathogeny and treatment of

THROMBOCYTHEMIA

UNDERSTANDING

MEGAKARYOCYTOPOIESIS

2004

Prof Christian CHATELAIN

UCL MONT-GODINNE

GP-IIbIIIa

D 14

GP-IIIa

CD34Forward vs side

Scatter (d14)

Cells

0

2000000

4000000

6000000

J0 J3 J7 J10 J14

Platelets

0

200000000

400000000

600000000

800000000

1000000000

J0 J3 J7 J10 J14

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

IL-1α induces thrombopoiesis through megakaryocyte rupture in response to

acute platelet needs

Nishimura S1 Nagasaki M2 Kunishima S3 Sawaguchi A4 Sakata A5 Sakaguchi H6

Ohmori T5 Manabe I7 Italiano JE Jr8 Ryu T9 Takayama N10 Komuro I2

Kadowaki T2 Eto K11 Nagai R5

J Cell Biol 2015 May 11209(3)453-66

RUPTURE MEGACARYOCYTAIRE

En guise de conclusion

DIAGNOSTIC Drsquo

HYPERPLAQUETTOSE

La production

des

plaquettes sanguines

Jeudis de Fleurus 2016

Prof Christian CHATELAIN

NTHC

Universiteacute de Namur

POLYPLOIDISATION

MECHANISM

Role of cytoskeletton

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

HYDROXYUREA DECREASES

PROLIFERATION

ANAGRELIDE DECREASES

POLYPLOIDIZATION

PSC CFU-MKMegakaryocytes Platelets

HUDROXYUREA

ANAGRELIDE

THERAPY OF ET

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

Do not forget HYPERURICEMIA

(Allopurinol)

What about PLATELET FUNCTIONS

Pathogeny and treatment of

THROMBOCYTHEMIA

UNDERSTANDING

MEGAKARYOCYTOPOIESIS

2004

Prof Christian CHATELAIN

UCL MONT-GODINNE

GP-IIIa

CD34Forward vs side

Scatter (d14)

Cells

0

2000000

4000000

6000000

J0 J3 J7 J10 J14

Platelets

0

200000000

400000000

600000000

800000000

1000000000

J0 J3 J7 J10 J14

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

IL-1α induces thrombopoiesis through megakaryocyte rupture in response to

acute platelet needs

Nishimura S1 Nagasaki M2 Kunishima S3 Sawaguchi A4 Sakata A5 Sakaguchi H6

Ohmori T5 Manabe I7 Italiano JE Jr8 Ryu T9 Takayama N10 Komuro I2

Kadowaki T2 Eto K11 Nagai R5

J Cell Biol 2015 May 11209(3)453-66

RUPTURE MEGACARYOCYTAIRE

En guise de conclusion

DIAGNOSTIC Drsquo

HYPERPLAQUETTOSE

La production

des

plaquettes sanguines

Jeudis de Fleurus 2016

Prof Christian CHATELAIN

NTHC

Universiteacute de Namur

POLYPLOIDISATION

MECHANISM

Role of cytoskeletton

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

HYDROXYUREA DECREASES

PROLIFERATION

ANAGRELIDE DECREASES

POLYPLOIDIZATION

PSC CFU-MKMegakaryocytes Platelets

HUDROXYUREA

ANAGRELIDE

THERAPY OF ET

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

Do not forget HYPERURICEMIA

(Allopurinol)

What about PLATELET FUNCTIONS

Pathogeny and treatment of

THROMBOCYTHEMIA

UNDERSTANDING

MEGAKARYOCYTOPOIESIS

2004

Prof Christian CHATELAIN

UCL MONT-GODINNE

Cells

0

2000000

4000000

6000000

J0 J3 J7 J10 J14

Platelets

0

200000000

400000000

600000000

800000000

1000000000

J0 J3 J7 J10 J14

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

IL-1α induces thrombopoiesis through megakaryocyte rupture in response to

acute platelet needs

Nishimura S1 Nagasaki M2 Kunishima S3 Sawaguchi A4 Sakata A5 Sakaguchi H6

Ohmori T5 Manabe I7 Italiano JE Jr8 Ryu T9 Takayama N10 Komuro I2

Kadowaki T2 Eto K11 Nagai R5

J Cell Biol 2015 May 11209(3)453-66

RUPTURE MEGACARYOCYTAIRE

En guise de conclusion

DIAGNOSTIC Drsquo

HYPERPLAQUETTOSE

La production

des

plaquettes sanguines

Jeudis de Fleurus 2016

Prof Christian CHATELAIN

NTHC

Universiteacute de Namur

POLYPLOIDISATION

MECHANISM

Role of cytoskeletton

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

HYDROXYUREA DECREASES

PROLIFERATION

ANAGRELIDE DECREASES

POLYPLOIDIZATION

PSC CFU-MKMegakaryocytes Platelets

HUDROXYUREA

ANAGRELIDE

THERAPY OF ET

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

Do not forget HYPERURICEMIA

(Allopurinol)

What about PLATELET FUNCTIONS

Pathogeny and treatment of

THROMBOCYTHEMIA

UNDERSTANDING

MEGAKARYOCYTOPOIESIS

2004

Prof Christian CHATELAIN

UCL MONT-GODINNE

CHRONOLOGIE1881 Identification des plaquettes (Bizzozero)

1910 Meacutegacaryocyte (Wright)

1958 Thrombopoiumleacutetine (Kelemen)

1967 Mesure de la production plaquettaire (Odell)

1968 Morphometrie des meacutegakaryocytes (Harker)

1975 CFU-MK (Metcalf)

1984 Cytokines (IL-3hellip) (Ihle Quesenberry)

1994 mpl et Thrombopoiumleacutetine

2016 rupture meacutegacaryocytaire (IL-1α)

IL-1α induces thrombopoiesis through megakaryocyte rupture in response to

acute platelet needs

Nishimura S1 Nagasaki M2 Kunishima S3 Sawaguchi A4 Sakata A5 Sakaguchi H6

Ohmori T5 Manabe I7 Italiano JE Jr8 Ryu T9 Takayama N10 Komuro I2

Kadowaki T2 Eto K11 Nagai R5

J Cell Biol 2015 May 11209(3)453-66

RUPTURE MEGACARYOCYTAIRE

En guise de conclusion

DIAGNOSTIC Drsquo

HYPERPLAQUETTOSE

La production

des

plaquettes sanguines

Jeudis de Fleurus 2016

Prof Christian CHATELAIN

NTHC

Universiteacute de Namur

POLYPLOIDISATION

MECHANISM

Role of cytoskeletton

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

HYDROXYUREA DECREASES

PROLIFERATION

ANAGRELIDE DECREASES

POLYPLOIDIZATION

PSC CFU-MKMegakaryocytes Platelets

HUDROXYUREA

ANAGRELIDE

THERAPY OF ET

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

Do not forget HYPERURICEMIA

(Allopurinol)

What about PLATELET FUNCTIONS

Pathogeny and treatment of

THROMBOCYTHEMIA

UNDERSTANDING

MEGAKARYOCYTOPOIESIS

2004

Prof Christian CHATELAIN

UCL MONT-GODINNE

IL-1α induces thrombopoiesis through megakaryocyte rupture in response to

acute platelet needs

Nishimura S1 Nagasaki M2 Kunishima S3 Sawaguchi A4 Sakata A5 Sakaguchi H6

Ohmori T5 Manabe I7 Italiano JE Jr8 Ryu T9 Takayama N10 Komuro I2

Kadowaki T2 Eto K11 Nagai R5

J Cell Biol 2015 May 11209(3)453-66

RUPTURE MEGACARYOCYTAIRE

En guise de conclusion

DIAGNOSTIC Drsquo

HYPERPLAQUETTOSE

La production

des

plaquettes sanguines

Jeudis de Fleurus 2016

Prof Christian CHATELAIN

NTHC

Universiteacute de Namur

POLYPLOIDISATION

MECHANISM

Role of cytoskeletton

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

HYDROXYUREA DECREASES

PROLIFERATION

ANAGRELIDE DECREASES

POLYPLOIDIZATION

PSC CFU-MKMegakaryocytes Platelets

HUDROXYUREA

ANAGRELIDE

THERAPY OF ET

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

Do not forget HYPERURICEMIA

(Allopurinol)

What about PLATELET FUNCTIONS

Pathogeny and treatment of

THROMBOCYTHEMIA

UNDERSTANDING

MEGAKARYOCYTOPOIESIS

2004

Prof Christian CHATELAIN

UCL MONT-GODINNE

En guise de conclusion

DIAGNOSTIC Drsquo

HYPERPLAQUETTOSE

La production

des

plaquettes sanguines

Jeudis de Fleurus 2016

Prof Christian CHATELAIN

NTHC

Universiteacute de Namur

POLYPLOIDISATION

MECHANISM

Role of cytoskeletton

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

HYDROXYUREA DECREASES

PROLIFERATION

ANAGRELIDE DECREASES

POLYPLOIDIZATION

PSC CFU-MKMegakaryocytes Platelets

HUDROXYUREA

ANAGRELIDE

THERAPY OF ET

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

Do not forget HYPERURICEMIA

(Allopurinol)

What about PLATELET FUNCTIONS

Pathogeny and treatment of

THROMBOCYTHEMIA

UNDERSTANDING

MEGAKARYOCYTOPOIESIS

2004

Prof Christian CHATELAIN

UCL MONT-GODINNE

La production

des

plaquettes sanguines

Jeudis de Fleurus 2016

Prof Christian CHATELAIN

NTHC

Universiteacute de Namur

POLYPLOIDISATION

MECHANISM

Role of cytoskeletton

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

HYDROXYUREA DECREASES

PROLIFERATION

ANAGRELIDE DECREASES

POLYPLOIDIZATION

PSC CFU-MKMegakaryocytes Platelets

HUDROXYUREA

ANAGRELIDE

THERAPY OF ET

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

Do not forget HYPERURICEMIA

(Allopurinol)

What about PLATELET FUNCTIONS

Pathogeny and treatment of

THROMBOCYTHEMIA

UNDERSTANDING

MEGAKARYOCYTOPOIESIS

2004

Prof Christian CHATELAIN

UCL MONT-GODINNE

POLYPLOIDISATION

MECHANISM

Role of cytoskeletton

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

HYDROXYUREA DECREASES

PROLIFERATION

ANAGRELIDE DECREASES

POLYPLOIDIZATION

PSC CFU-MKMegakaryocytes Platelets

HUDROXYUREA

ANAGRELIDE

THERAPY OF ET

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

Do not forget HYPERURICEMIA

(Allopurinol)

What about PLATELET FUNCTIONS

Pathogeny and treatment of

THROMBOCYTHEMIA

UNDERSTANDING

MEGAKARYOCYTOPOIESIS

2004

Prof Christian CHATELAIN

UCL MONT-GODINNE

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

HYDROXYUREA DECREASES

PROLIFERATION

ANAGRELIDE DECREASES

POLYPLOIDIZATION

PSC CFU-MKMegakaryocytes Platelets

HUDROXYUREA

ANAGRELIDE

THERAPY OF ET

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

Do not forget HYPERURICEMIA

(Allopurinol)

What about PLATELET FUNCTIONS

Pathogeny and treatment of

THROMBOCYTHEMIA

UNDERSTANDING

MEGAKARYOCYTOPOIESIS

2004

Prof Christian CHATELAIN

UCL MONT-GODINNE

PSC CFU-MKMegakaryocytes Platelets

HUDROXYUREA

ANAGRELIDE

THERAPY OF ET

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

Do not forget HYPERURICEMIA

(Allopurinol)

What about PLATELET FUNCTIONS

Pathogeny and treatment of

THROMBOCYTHEMIA

UNDERSTANDING

MEGAKARYOCYTOPOIESIS

2004

Prof Christian CHATELAIN

UCL MONT-GODINNE

TREATMENT OF

ESSENTIAL

THROMBOCYTHEMIA

Do not forget HYPERURICEMIA

(Allopurinol)

What about PLATELET FUNCTIONS

Pathogeny and treatment of

THROMBOCYTHEMIA

UNDERSTANDING

MEGAKARYOCYTOPOIESIS

2004

Prof Christian CHATELAIN

UCL MONT-GODINNE

Pathogeny and treatment of

THROMBOCYTHEMIA

UNDERSTANDING

MEGAKARYOCYTOPOIESIS

2004

Prof Christian CHATELAIN

UCL MONT-GODINNE

top related